

## PUBLICATIONS CLB - CRCL 2014

1. Abeillon-du PJ, Caron P, Borson-Chazot F: [What's new in follicular thyroid cancer management in 2014?]. *Ann Endocrinol (Paris)* 75 Suppl 1:S2-12, 2014
2. Abeillon-du PJ, Chikh K, Bossard N, Bretones P, Gaucherand P, Claris O, Charrie A, Raverot V, Orgiazzi J, Borson-Chazot F, Bournaud C: Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism. *Eur J Endocrinol* 171:451-460, 2014
3. Adenis A, Blay JY, Bui-Nguyen B, Bouche O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blesius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le CA: Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. *Ann Oncol* 25:1762-1769, 2014
4. Albiges L, Izzedine H, Ederhy S, Robert C, Gravis G, Boyle H, Scotte F, Hartl D, Escudier B: [Axitinib in metastatic renal carcinomas: update of knowledge about side effects]. *Bull Cancer* 101:976-988, 2014
5. Alcaraz LB, Exposito JY, Chuvin N, Pommier RM, Cluzel C, Martel S, Sentis S, Bartholin L, Lethias C, Valcourt U: Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-beta. *J Cell Biol* 205:409-428, 2014
6. Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B: Gynecologic Cancer InterGroup (GCIg) consensus review for endometrial stromal sarcoma. *Int J Gynecol Cancer* 24:S67-S72, 2014
7. Amet S, Bronowicki JP, Thabut D, Zoulim F, Bourliere M, Mathurin P, De L, V, Benhamou Y, Larrey DG, Janus N, Deray G, Launay-Vacher V, Pol S: Prevalence of renal abnormalities in chronic HBV infection: The HARPE study. *Liver Int* 2014
8. Andre F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, Adelaide J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonnetterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H: Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). *Lancet Oncol* 15:267-274, 2014

9. Angelergues A, Maillet D, Flechon A, Ozguroglu M, Mercier F, Guillot A, Le MS, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte RT, Delanoy N, Elaidi RT, Oudard S: Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. *Eur J Cancer* 50:1602-1609, 2014
10. Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van d, V, Tromp B, Vermeulen J, Kurzrock R: A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. *Clin Cancer Res* 20:2192-2204, 2014
11. Ansieau S, Collin G, Hill L: EMT or EMT-Promoting Transcription Factors, Where to Focus the Light? *Front Oncol* 4:353, 2014
12. Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van BF, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL: Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. *Gut* 2014
13. Arnaud C, Trepo C, Petit MA: Predictors of the therapeutic response in hepatitis C. A 2013 update. *Clin Res Hepatol Gastroenterol* 38:12-17, 2014
14. Avances C, Camparo P, Durand X, Flechon A, Murez T, Sebe P, Soulie M, Rigaud J: [Management of testicular teratoma: update by the Oncology Committee of the French Urology Association, section of External Genital Organs (CCAFU-OGE)]. *Prog Urol* 24:1050-1053, 2014
15. Avril MF, Bahadoran P, Cabaret O, Caron O, de la Fouchardiere A, Demenais F, Desjardins L, Frebourg T, Hammel P, Leccia MT, Lesueur F, Mahe E, Martin L, Maubec E, Remenieras A, Richard S, Robert C, Soufir N, Stoppa-Lyonnet D, Thomas L, Vabres P, Bressac-de PB: [Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma]. *Ann Dermatol Venereol* 142:26-36, 2015
16. Ayadi M, Zahra N, Thariat J, Bouilhol G, Boissard P, Van HP, Claude L, Mornex F: [Intensity-modulated radiation therapy in non-small cell lung cancers]. *Cancer Radiother* 18:406-413, 2014
17. Bachelot T, Garcia-Saenz JA, Verma S, Gutierrez M, Pivot X, Kozloff MF, Prady C, Huang X, Khosravan R, Wang Z, Cesari R, Tassell V, Kern KA, Blay JY, Lluch A: Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. *BMC Cancer* 14:166, 2014

18. Bachelot T, McCool R, Duffy S, Glanville J, Varley D, Fleetwood K, Zhang J, Jerusalem G: Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. *Breast Cancer Res Treat* 143:125-133, 2014
19. Badaoui N, Meyronet D, Cartalat-Carel S, Guyotat J, Jouanneau E, d'Hombres A, Sunyach MP, Jouvet A, Louis-Tisserand G, Archinet A, Frappaz D, Bauchet L, Honnorat J, Ducray F: Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France. *Rev Neurol (Paris)* 170:222-227, 2014
20. Balan S, Ollion V, Colletti N, Chelbi R, Montanana-Sanchis F, Liu H, Vu Manh TP, Sanchez C, Savoret J, Perrot I, Doffin AC, Fossum E, Bechlian D, Chabannon C, Bogen B, Asselin-Paturel C, Shaw M, Soos T, Caux C, Valladeau-Guilemond J, Dalod M: Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells. *J Immunol* 193:1622-1635, 2014
21. Baldacci F, Mittone A, Bravin A, Coan P, Delaire F, Ferrero C, Gasilov S, Letang JM, Sarrut D, Smekens F, Freud N: A track length estimator method for dose calculations in low-energy X-ray irradiations: implementation, properties and performance. *Z Med Phys* 25:36-47, 2015
22. Barau C, Braun J, Vincent C, Haim-Boukobza S, Molina JM, Mialhes P, Fournier I, Aboulker JP, Vittecoq D, Duclos-Vallee JC, Taburet AM, Teicher E: Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study. *Clin Infect Dis* 59:1177-1184, 2014
23. Barbare JC, Franco D, Andre T, Bronowicki JP, Merle P, Peron JM, Raoul JL, Seitz JF, Ychou M: Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings? *Bull Cancer* 101:558-563, 2014
24. Bardet JD, Charpiat B, Bedouch P, Rebillon M, Ducerf C, Gauchet A, Tourette-Turgis C, Allenet B: Illness representation and treatment beliefs in liver transplantation: an exploratory qualitative study. *Ann Pharm Fr* 72:375-387, 2014
25. Barrdahl M, Canzian F, Joshi AD, Travis RC, Chang-Claude J, Auer PL, Gapstur SM, Gaudet M, Diver WR, Henderson BE, Haiman CA, Schumacher FR, Le ML, Berg CD, Chanock SJ, Hoover RN, Rudolph A, Ziegler RG, Giles GG, Baglietto L, Severi G, Hankinson SE, Lindstrom S, Willet W, Hunter DJ, Buring JE, Lee IM, Zhang S, Dossus L, Cox DG, Khaw KT, Lund E, Naccarati A, Peeters PH, Quiros JR, Riboli E, Sund M, Trichopoulos D, Prentice RL, Kraft P, Kaaks R, Campa D: Post-GWAS gene-environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort Consortium and a meta-analysis on 79,000 women. *Hum Mol Genet* 23:5260-5270, 2014

26. Bartosch B: Piecing together the key players of fibrosis in chronic hepatitis C: what roles do non-hepatic liver resident cell types play? *Gut* 2014
27. Baudin E, Caron P, Lombard-Bohas C, Tabarin A, Mitry E, Reznick Y, Taieb D, Pattou F, Goudet P, Vezzosi D, Scoazec JY, Cadiot G, Borson-Chazot F, Do CC: Malignant insulinoma: Recommendations for workup and treatment. *Presse Med* 43:645-659, 2014
28. Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de FF, Bieche I, de CP, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranet J: A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non-Small Cell Lung Cancer Setting-IFCT/ERMETIC2 Project Part 1: Comparison of Testing Methods in 20 French Molecular Genetic National Cancer Institute Platforms. *J Mol Diagn* 16:45-55, 2014
29. Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, Thomas X, Cayuela JM, Gardel N, Chalandon Y, Boissel N, Schaefer B, Delabesse E, Cave H, Chevallier P, Buzyn A, Fest T, Reman O, Vernant JP, Lheritier V, Bene MC, Lafage M, Macintyre E, Ifrah N, Dombret H: Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. *Blood* 123:3739-3749, 2014
30. Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litiere S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le PC, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van GM, Woll P, Gourgou-Bourgade S, Mathoulin-Pelissier S: Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)dagger. *Ann Oncol* 26:865-872, 2015
31. Ben AM, Minard-Colin V, Mosseri V, Defachelles AS, Bergeron C, Algret N, Fasola S, Andre N, Thebaud E, Corradini N, Bernier V, Martelli H, Ranchere D, Orbach D: Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? *Eur J Cancer* 51:193-201, 2015
32. Benaim G, Castillo C, Houang M, Dejardin L, Mateus C, Wang Q, Pissaloux D, Tomasic G, Cribier B, de la Fouchardiere A: Melanoma arising from a long-standing pigmented trichoblastoma: clinicopathologic study with complementary aCGH/mutational analysis. *Am J Dermatopathol* 36:e146-e151, 2014

33. Beranger R, Blain J, Baudinet C, Faure E, Flechon A, Boyle H, Chasles V, Charbotel B, Schuz J, Fervers B: [Testicular germ cell tumours and early exposures to pesticides: The TESTEPERA pilot study]. *Bull Cancer* 101:225-235, 2014
34. Beranger R, Perol O, Bujan L, Faure E, Blain J, Le CC, Flechon A, Charbotel B, Philip T, Schuz J, Fervers B: Studying the impact of early life exposures to pesticides on the risk of testicular germ cell tumors during adulthood (TESTIS project): study protocol. *BMC Cancer* 14:563, 2014
35. Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinou KM, Dinh P, Flaherty JF, Jr., McHutchison JG, Manns M: Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. *J Hepatol* 60:715-722, 2014
36. Bernard D, Vindrieux D: PLA2R1: expression and function in cancer. *Biochim Biophys Acta* 1846:40-44, 2014
37. Biarc J, Gonzalo P, Mikaelian I, Fattet L, Deygas M, Gillet G, Lemoine J, Rimokh R: Combination of a discovery LC-MS/MS analysis and a label-free quantification for the characterization of an epithelial-mesenchymal transition signature. *J Proteomics* 110:183-194, 2014
38. Bidard FC, Tredan O: Trends in cancer-targeted antibody-drug conjugates. *Target Oncol* 9:1-8, 2014
39. Binachon B, Dossus L, Danjou AM, Clavel-Chapelon F, Fervers B: Life in urban areas and breast cancer risk in the French E3N cohort. *Eur J Epidemiol* 29:743-751, 2014
40. Blaising J, Polyak SJ, Pecheur EI: Arbidol as a broad-spectrum antiviral: an update. *Antiviral Res* 107:84-94, 2014
41. Blay JY, Casali P, Nieto A, Tanovic A, Le CA: Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. *Future Oncol* 10:59-68, 2014
42. Blay JY, Derbel O, Ray-Coquard I: The clinician's perspective on sarcoma pathology reporting: impact on treatment decisions? *Pathology* 46:121-125, 2014
43. Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, Staddon AP, Penel N, Piperno-Neumann S, Hendifar A, Lardelli P, Nieto A, Alfaro V, Chawla SP: Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. *Eur J Cancer* 50:1137-1147, 2014
44. Blay JY, Rutkowski P: Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. *Cancer Treat Rev* 40:242-247, 2014

45. Blay JY, Sleijfer S, Schoffski P, Kawai A, Brodowicz T, Demetri GD, Maki RG: International expert opinion on patient-tailored management of soft tissue sarcomas. *Eur J Cancer* 50:679-689, 2014
46. Blay JY: Going further in the knowledge of Yondelis(R); what's new in clinical trials? *Future Oncol* 10:s7-s12, 2014
47. Blay JY: Oncogenes, tumor suppressor genes, and aneuploidy: the sum of the nuances. *Bull Cancer* 101:340, 2014
48. Bodgi L, Foray N: On the coherence between mathematical models of DSB repair and physiological reality. *Mutat Res* 761:48-49, 2014
49. Bodnar, M. and Petrilli, V. New insights in caspase-11 functions in noncanonical inflammasome signalling. *Inflammasome* . 2014.
50. Boettler T, Moradpour D, Thimme R, Zoulim F: Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis. *J Hepatol* 61:696-705, 2014
51. Boettler T, Moradpour D, Thimme R, Zoulim F: Bridging basic science and clinical research - The EASL Monothematic Conference on Translational Research in Viral Hepatitis. *J Hepatol* 2014
52. Bollotte A, Vial T, Bricca P, Bernard C, Broussolle C, Seve P: [Drug-induced immune haemolytic anemia: a retrospective study of 10 cases]. *Rev Med Interne* 35:779-789, 2014
53. Bonneau B, Nougarede A, Prudent J, Popgeorgiev N, Peyrieras N, Rimokh R, Gillet G: The Bcl-2 homolog Nr3 inhibits binding of IP3 to its receptor to control calcium signaling during zebrafish epiboly. *Sci Signal* 7:ra14, 2014
54. Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina CG, Slaets L, Cameron D: Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. *Ann Oncol* 26:325-332, 2015
55. Borson-Chazot F, Caron P, Glinoeur D, Wemeau JL: Antithyroid drugs: what kind of prescription? *Presse Med* 43:105-108, 2014
56. Bouard C, Terreux R, Hope J, Chemelle JA, Puisieux A, Ansieau S, Payen L: Interhelical loops within the bHLH domain are determinant in maintaining TWIST1-DNA complexes. *J Biomol Struct Dyn* 32:226-241, 2014

57. Bouchekioua-Bouzaghrou K, Poulard C, Rambaud J, Lavergne E, Hussein N, Billaud M, Bachelot T, Chabaud S, Mader S, Dayan G, Treilleux I, Corbo L, Le RM: LKB1 when associated with methylatedERalpha is a marker of bad prognosis in breast cancer. *Int J Cancer* 135:1307-1318, 2014
58. Bounin A, Charbotel B, Fervers B, Bergeret A: [Professional risk factors associated with the cancer of the ovary. Literature review]. *Bull Cancer* 101:1089-1108, 2014
59. Boyd A, Gozlan J, Maylin S, Delaugerre C, Peytavin G, Girard PM, Zoulim F, Lacombe K: Persistent viremia in human immunodeficiency virus/hepatitis B coinfecting patients undergoing long-term tenofovir: virological and clinical implications. *Hepatology* 60:497-507, 2014
60. Boyer JC, Etienne-Grimaldi MC, Thomas F, Quaranta S, Picard N, Lorient MA, Poncet D, Gagnieu MC, Ged C, Broly F, Le M, V, Bouquie R, Gaub MP, Philibert L, Ghiringhelli F, Le GC: Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan. *Bull Cancer* 101:533-553, 2014
61. Boyrie S, Charra-Brunaud C, Harter V, Ducassou A, Kirova Y, Barillot I, Krzisch C, Lang P, Baron MH, Montbarbon X, Delannes M, Peiffert D: Impact of dosimetric parameters on local control for patients treated with three-dimensional pulsed dose-rate brachytherapy for cervical cancer. *Brachytherapy* 13:326-331, 2014
62. Brault C, Levy P, Duponchel S, Michelet M, Salle A, Pecheur EI, Plissonnier ML, Parent R, Vericel E, Ivanov AV, Demir M, Steffen HM, Odenthal M, Zoulim F, Bartosch B: Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity. *Gut* 2014
63. Breton AL, Amini-Adle M, Duru G, Poulalhon N, Dalle S, Thomas L: Overview of the use of dermoscopy in academic and non-academic hospital centres in France: a nationwide survey. *J Eur Acad Dermatol Venereol* 28:1207-1213, 2014
64. Brisou G, Manzoni D, Dalle S, Felman P, Morel D, Boubaya M, Magaud JP, Baseggio L: Alarms and Parameters Generated by Hematology Analyzer: New Tools to Predict and Quantify Circulating Sezary Cells. *J Clin Lab Anal* 2014
65. Brown RJ, Koutsoudakis G, Urbanowicz RA, Mirza D, Ginkel C, Riebesehl N, Calland N, Albecka A, Price L, Hudson N, Descamps V, Backx M, McClure CP, Duverlie G, Pecheur EI, Dubuisson J, Perez-del-Pulgar S, Fornis X, Steinmann E, Tarr AW, Pietschmann T, Ball JK: Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution. *J Virol* 88:667-678, 2014
66. Buffaz C, Scholtes C, Dron AG, Chevallier-Queyron P, Ritter J, Andre P, Ramiere C: Hepatitis E in liver transplant recipients in the Rhone-Alpes region in France. *Eur J Clin Microbiol Infect Dis* 33:1037-1043, 2014

67. Bureau E, Pellegrini I, Nogues C, Lasset C, Julian-Reynier C: "Maybe they have found something new" participants' views on returning cohort psychosocial survey results. *Health Expect* 2014
68. Bylicki O, Gan HK, Joly F, Maillet D, You B, Peron J: Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. *Ann Oncol* 26:231-237, 2015
69. Campa D, Barrdahl M, Tsilidis KK, Severi G, Diver WR, Siddiq A, Chanock S, Hoover RN, Ziegler RG, Berg CD, Buys SS, Haiman CA, Henderson BE, Schumacher FR, Le ML, Flesch-Janys D, Lindstrom S, Hunter DJ, Hankinson SE, Willett WC, Kraft P, Cox DG, Khaw KT, Tjonneland A, Dossus L, Trichopoulos D, Panico S, van Gils CH, Weiderpass E, Barricarte A, Sund M, Gaudet MM, Giles G, Southey M, Baglietto L, Chang-Claude J, Kaaks R, Canzian F: A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. *PLoS One* 9:e85955, 2014
70. Campillo VE, Langonnet S, Pierrefeu A, Chaux-Bodard AG: Anatomic and histological study of the rabbit mandible as an experimental model for wound healing and surgical therapies. *Lab Anim* 48:273-277, 2014
71. Cannas G, Thomas X: Supportive care in patients with acute leukaemia: historical perspectives. *Blood Transfus* 1-16, 2014
72. Cano CE, Hamidi T, Garcia MN, Grasso D, Loncle C, Garcia S, Calvo E, Lomberk G, Duseti N, Bartholin L, Urrutia R, Iovanna JL: Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis. *Gut* 63:984-995, 2014
73. Caplain A, Drouet Y, Peyron M, Peix M, Faure C, Chassagne-Clement C, Beurrier F, Fondrevelle ME, Guerin N, Lasset C, Treilleux I: Management of patients diagnosed with atypical ductal hyperplasia by vacuum-assisted core biopsy: a prospective assessment of the guidelines used at our institution. *Am J Surg* 208:260-267, 2014
74. Caratozzolo MF, Valletti A, Gigante M, Aiello I, Mastropasqua F, Marzano F, Ditonno P, Carrieri G, Simonnet H, D'Erchia AM, Ranieri E, Pesole G, Sbisà E, Tullo A: TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma. *Oncotarget* 5:7446-7457, 2014
75. Carrera C, Bennassar A, Ishioka P, Dalle S, Vilalta A, Fuertes I, Alos L, Thomas L, Puig S, Malvehy J: Desmoplastic melanoma on the nose: electrochemotherapy as an alternative treatment to local advanced disease. *J Eur Acad Dermatol Venereol* 28:424-432, 2014
76. Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, Bonnard P, Salmon D, Dabis F, Spire B: Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected



- individuals: results from the ANRS CO13 HEPAVIH cohort study. *J Hepatol* 60:46-53, 2014
77. Casali PG, Bruzzi P, Bogaerts J, Blay JY: Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. *Ann Oncol* 26:300-306, 2015
  78. Cassier PA, Floquet A, Penel N, Derbel O, Bui NB, Guastalla JP, Pissaloux D, Treilleux I, Saba CE, Blay JY, Ray-Coquard I: The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors. *Ann Oncol* 25:1074-1075, 2014
  79. Cassier PA, Kantor G, Bonvalot S, Lavergne E, Stoeckle E, Le PC, Meeus P, Sunyach MP, Vaz G, Coindre JM, Linassier C, Labib A, Delcambre C, Bay JO, Leyvraz S, Duberge T, Lagrange JL, Duret A, Blay JY: Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study. *Ann Oncol* 25:1854-1860, 2014
  80. Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schoffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D: Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database. *Ann Oncol* 25:1222-1228, 2014
  81. Catez F, Rousseau A, Labetoulle M, Lomonte P: Detection of the genome and transcripts of a persistent DNA virus in neuronal tissues by fluorescent in situ hybridization combined with immunostaining. *J Vis Expe* 51091, 2014
  82. Cellupica M: [Doctor-nurse delegation of the insertion of central venous lines]. *Rev Infirm* 207:36-39, 2015
  83. Cerhan JR, Berndt SI, Vijai J, Ghesquieres H, McKay J, Wang SS, Wang Z, Yeager M, Conde L, de Bakker PI, Nieters A, Cox D, Burdett L, Monnereau A, Flowers CR, De Roos AJ, Brooks-Wilson AR, Lan Q, Severi G, Melbye M, Gu J, Jackson RD, Kane E, Teras LR, Purdue MP, Vajdic CM, Spinelli JJ, Giles GG, Albanes D, Kelly RS, Zucca M, Bertrand KA, Zeleniuch-Jacquotte A, Lawrence C, Hutchinson A, Zhi D, Habermann TM, Link BK, Novak AJ, Dogan A, Asmann YW, Liebow M, Thompson CA, Ansell SM, Witzig TE, Weiner GJ, Veron AS, Zelenika D, Tilly H, Haioun C, Molina TJ, Hjalgrim H, Glimelius B, Adami HO, Bracci PM, Riby J, Smith MT, Holly EA, Cozen W, Hartge P, Morton LM, Severson RK, Tinker LF, North KE, Becker N, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, Lightfoot T, Crouch S, Smith A, Roman E, Diver WR, Offit K, Zelenetz A, Klein RJ, Villano DJ, Zheng T, Zhang Y, Holford TR, Krickler A, Turner J, Southey MC, Clavel J, Virtamo J, Weinstein S, Riboli E, Vineis P, Kaaks R, Trichopoulos D, Vermeulen RC, Boeing H, Tjonneland A, Angelucci E, Di LS, Rais M, Birmann BM, Laden

- F, Giovannucci E, Kraft P, Huang J, Ma B, Ye Y, Chiu BC, Sampson J, Liang L, Park JH, Chung CC, Weisenburger DD, Chatterjee N, Fraumeni JF, Jr., Slager SL, Wu X, de SS, Smedby KE, Salles G, Skibola CF, Rothman N, Chanock SJ: Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. *Nat Genet* 46:1233-1238, 2014
84. Cettier J, Bayle ML, Beranger R, Billoir E, Nuckols JR, Combourieu B, Fervers B: Efficiency of wipe sampling on hard surfaces for pesticides and PCB residues in dust. *Sci Total Environ* 505:11-21, 2015
  85. Chaabane F, Krifa M, Matera E, Loussaeif A, Dijoux-Franca MG, Ghedira K, Dumontet C, Chekir-Ghedira L: In vitro antileukaemic activity of extracts from *Daphne gnidium* leaves against sensitive and multidrug resistant K562/R7 cells. *Tumour Biol* 35:8991-8998, 2014
  86. Chakiba C, Lagarde P, Pissaloux D, Neuville A, Brulard C, Perot G, Coindre JM, Terrier P, Ranchere-Vince D, Ferrari A, Collini P, Suurmeijer AJ, Blay JY, Terrisse SA, Piperno-Neumann S, Averous G, Bui B, Orbach D, Italiano A, Chibon F: Response to chemotherapy is not related to chromosome instability in synovial sarcoma. *Ann Oncol* 25:2267-2271, 2014
  87. Chamoun-Emanuelli AM, Pecheur EI, Chen Z: Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus. *Antiviral Res* 109:141-148, 2014
  88. Chapat C, Corbo L: Novel roles of the CCR4-NOT complex. *Wiley Interdiscip Rev RNA* 5:883-901, 2014
  89. Chapat C, Corbo L: Novel roles of the CCR4-NOT complex. *Wiley Interdiscip Rev RNA* 5:883-901, 2014
  90. Charbotel B, Fervers B, Droz JP: Occupational exposures in rare cancers: A critical review of the literature. *Crit Rev Oncol Hematol* 90:99-134, 2014
  91. Charuworn P, Hengen PN, Aguilar SR, Dinh P, Ge D, Corsa A, Reesink HW, Zoulim F, Kitrinou KM: Baseline Interpatient Hepatitis B Viral Diversity Differentiates HBsAg Outcomes in Patients Treated With Tenofovir Disoproxil Fumarate. *J Hepatol* 2014
  92. Chen XL, Chinchilla P, Fombonne J, Ho L, Guix C, Keen JH, Mehlen P, Riobo NA: Patched-1 proapoptotic activity is downregulated by modification of K1413 by the E3 ubiquitin-protein ligase Itchy homolog. *Mol Cell Biol* 34:3855-3866, 2014
  93. Chevreau C, Ravaud A, Escudier B, Amela E, Delva R, Rolland F, Tosi D, Oudard S, Blanc E, Ferlay C, Negrier S: A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. *Clin Genitourin Cancer* 12:50-54, 2014

94. Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, Corre J: Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. *Haematologica* 99:1236-1238, 2014
95. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haim-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallee JC: Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. *J Hepatol* 60:78-86, 2014
96. Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I: Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. *Crit Rev Oncol Hematol* 89:207-216, 2014
97. Combemale P, Valeyrie-Allanore L, Giammarile F, Pinson S, Guillot B, Goulart DM, Wolkenstein P, Blay JY, Mognetti T: Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1. *PLoS One* 9:e85954, 2014
98. Confavreux CB, Girard N, Pialat JB, Bringuier PP, Devouassoux-Shisheboran M, Rousseau JC, Isaac S, Thivolet-Bejui F, Clezardin P, Brevet M: Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). *Bonekey Rep* 3:580, 2014
99. Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A: Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 15:305-314, 2014
100. Couderc C, Bollard J, Coute Y, Massoma P, Poncet G, Lepinasse F, Hervieu V, Gadot N, Sanchez JC, Scoazec JY, Diaz JJ, Roche C: Mechanisms of local invasion in enteroendocrine tumors: identification of novel candidate cytoskeleton-associated proteins in an experimental mouse model by a proteomic approach and validation in human tumors. *Mol Cell Endocrinol* 399:154-163, 2015
101. Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupre PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A: Use of [(18)F]-FDG PET to predict response to

- neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. *Lancet Oncol* 15:1493-1502, 2014
102. Coudurier J, Ho QC, Ismail M, Dlimi C, Tourasse C, Delay E: [Long-term outcome of lipomodelling in Poland's syndrome: about our first case with an eleven-years' follow-up]. *Ann Chir Plast Esthet* 60:65-69, 2015
  103. Cova L: Advances and challenges in the development of therapeutic DNA vaccines against hepatitis B virus infection. *Curr Gene Ther* 14:149-160, 2014
  104. Cozen W, Timofeeva MN, Li D, Diepstra A, Hazelett D, Delahaye-Sourdeix M, Edlund CK, Franke L, Rostgaard K, Van Den Berg DJ, Cortessis VK, Smedby KE, Glaser SL, Westra HJ, Robison LL, Mack TM, Ghesquieres H, Hwang AE, Nieters A, de SS, Lightfoot T, Becker N, Maynadie M, Foretova L, Roman E, Benavente Y, Rand KA, Nathwani BN, Glimelius B, Staines A, Boffetta P, Link BK, Kiemeny L, Ansell SM, Bhatia S, Strong LC, Galan P, Vatten L, Habermann TM, Duell EJ, Lake A, Veenstra RN, Visser L, Liu Y, Urayama KY, Montgomery D, Gaborieau V, Weiss LM, Byrnes G, Lathrop M, Cocco P, Best T, Skol AD, Adami HO, Melbye M, Cerhan JR, Gallagher A, Taylor GM, Slager SL, Brennan P, Coetzee GA, Conti DV, Onel K, Jarrett RF, Hjalgrim H, van den Berg A, McKay JD: A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. *Nat Commun* 5:3856, 2014
  105. Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A, Clezardin P: TWIST1 Expression in Breast Cancer Cells Facilitates Bone Metastasis Formation. *J Bone Miner Res* 2014
  106. da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloureaux P, Sangrajang S, Khuhaprema T, Mendy M, Lesi OA, Chang HK, Oh JK, Lee DH, Shin HR, Kirk GD, Merle P, Beretta L, Hainaut P: Osteopontin and latent-TGF beta binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. *Int J Cancer* 2014
  107. Dalonneau F, Liu XQ, Sadir R, Almodovar J, Mertani HC, Bruckert F, Albiges-Rizo C, Weidenhaupt M, Lortat-Jacob H, Picart C: The effect of delivering the chemokine SDF-1alpha in a matrix-bound manner on myogenesis. *Biomaterials* 35:4525-4535, 2014
  108. Dardenne E, Polay EM, Fattet L, Germann S, Lambert MP, Neil H, Zonta E, Mortada H, Gratadou L, Deygas M, Chakrama FZ, Samaan S, Desmet FO, Tranchevent LC, Dutertre M, Rimokh R, Bourgeois CF, Auboeuf D: RNA helicases DDX5 and DDX17 dynamically orchestrate transcription, miRNA, and splicing programs in cell differentiation. *Cell Rep* 7:1900-1913, 2014
  109. Darnis B, Rode A, Mohkam K, Ducerf C, Mabrut JY: Management of bleeding liver tumors. *J Visc Surg* 151:365-375, 2014

110. de la Fouchardiere A, Cabaret O, Savin L, Combemale P, Schwartz H, Penet C, Bonadona V, Soufir N, Bressac-de PB: Germline BAP1 mutations predispose also to multiple basal cell carcinomas. *Clin Genet* 88:273-277, 2015
111. de Masson A., Beylot-Barry M, Bouaziz JD, Peffault de LR, Aubin F, Garciaz S, d'Incan M, Dereure O, Dalle S, Dompmartin A, Suarez F, Battistella M, Vignon-Pennamen MD, Rivet J, Adamski H, Brice P, Francois S, Lissandre S, Turlure P, Wierzbicka-Hainaut E, Brissot E, Dulery R, Servais S, Ravinet A, Tabrizi R, Ingen-Housz-Oro S, Joly P, Socie G, Bagot M: Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. *Haematologica* 99:527-534, 2014
112. De Souza V, Hadj-Aissa A, Dolomanova O, Rabilloud M, Rognant N, Lemoine S, Radenne S, Dumortier J, Chapuis-Cellier C, Beyerle F, Bon C, Iwaz J, Selistre L, Dubourg L: Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. *Hepatology* 59:1522-1531, 2014
113. Deauvieu F, Ollion V, Doffin AC, Achard C, Fonteneau JF, Verronese E, Durand I, Ghittoni R, Marvel J, Dezutter-Dambuyant C, Walzer T, Vie H, Perrot I, Goutagny N, Caux C, Valladeau-Guilemond J: Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. *Int J Cancer* 136:1085-1094, 2015
114. Debarbieux S, Dalle S, Depaepe L, Jeannot PY, Poulalhon N, Thomas L: Extramammary Paget's disease of the scalp: examination by in vivo and ex vivo reflectance confocal microscopy. *Skin Res Technol* 20:124-126, 2014
115. Debarbieux S, Gaspar R, Depaepe L, Dalle S, Balme B, Thomas L: Intraoperative diagnosis of non pigmented nail tumors with ex vivo fluorescence confocal microscopy: about 10 cases. *Br J Dermatol* 2014
116. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V: SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. *Clin Cancer Res* 20:4574-4583, 2014
117. Decoster L, Van PK, Mohile S, Wedding U, Basso U, Colloca G, Rostoft S, Overcash J, Wildiers H, Steer C, Kimmick G, Kanavaras R, Luciani A, Terret C, Hurria A, Kenis C, Audisio R, Extermann M: Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. *Ann Oncol* 26:288-300, 2015

118. Decouvelaere AV: [Immunohistochemistry in the diagnosis of sarcomas]. *Ann Pathol* 35:98-106, 2015
119. Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Benard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van RN, Vicha A, Villamon E, Tonini GP: Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. *Br J Cancer* 112:290-295, 2015
120. Dejeans N, Manie S, Hetz C, Bard F, Hupp T, Agostinis P, Samali A, Chevet E: Addicted to secrete - novel concepts and targets in cancer therapy. *Trends Mol Med* 20:242-250, 2014
121. Delaunay J, Moulin C, Dalle S, Thomas L: Superficial basal cell carcinoma versus nodular basal cell carcinoma. *Ann Dermatol Venereol* 141:312-313, 2014
122. Delcourt C, Cougnard-Gregoire A, Boniol M, Carriere I, Dore JF, Delyfer MN, Rougier MB, Le GM, Dartigues JF, Barberger-Gateau P, Korobelnik JF: Lifetime exposure to ambient ultraviolet radiation and the risk for cataract extraction and age-related macular degeneration: the Alienor Study. *Invest Ophthalmol Vis Sci* 55:7619-7627, 2014
123. Delloye-Bourgeois C, Rama N, Brito J, Le DN, Mehlen P: Sonic Hedgehog promotes the survival of neural crest cells by limiting apoptosis induced by the dependence receptor CDON during branchial arch development. *Biochem Biophys Res Commun* 452:655-660, 2014
124. Delolme F, Anastasi C, Alcaraz LB, Mendoza V, Vadon-Le GS, Talantikite M, Capomaccio R, Mevaere J, Fortin L, Mazzocut D, Damour O, Zanella-Cleon I, Hulmes DJ, Overall CM, Valcourt U, Lopez-Casillas F, Moali C: Proteolytic control of TGF-beta co-receptor activity by BMP-1/tolloid-like proteases revealed by quantitative iTRAQ proteomics. *Cell Mol Life Sci* 2014
125. Dhilly M, Guillouet S, Patin D, Fillesoye F, Abbas A, Gourand F, Tirel O, Galateau F, Mackenzie ET, Dumontet C, Leporrier M, Barre L: 2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models. *Mol Imaging Biol* 16:118-126, 2014
126. Di Filippo M, Moulin P, Roy P, Samson-Bouma ME, Collardeau-Frachon S, Chebel-Dumont S, Peretti N, Dumortier J, Zoulim F, Fontanges T, Parini R, Rigoldi M, Furlan F, Mancini G, Bonnefont-Rousselot D, Bruckert E, Schmitz J, Scoazec JY, Charriere S, Villar-Fimbel S, Gottrand F, Dubern B, Doummar D, Joly F, Liard-Meillon ME, Lachaux A, Sassolas A: Homozygous MTTP and

- APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. *J Hepatol* 61:891-902, 2014
127. Dieras V, Bachelot T: The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. *Target Oncol* 9:111-122, 2014
  128. Disse E, Pasquer A, Espalieu P, Poncet G, Gouillat C, Robert M: Greater weight loss with the omega loop bypass compared to the Roux-en-Y gastric bypass: a comparative study. *Obes Surg* 24:841-846, 2014
  129. Douab T, Marcellin F, Vilotitch A, Protopopescu C, Preau M, Suzan-Monti M, Sagaon-Teyssier L, Lert F, Carrieri MP, Dray-Spira R, Spire B: Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys). *AIDS Care* 26 Suppl 1:S29-S40, 2014
  130. Drouet A, Le MF, Salame D, Quesnel L, Motolese C, des P, V, Guilloton L, Pinson S: [Type 2 neurofibromatosis: intergenerational differences in genetic and clinical expression]. *Arch Pediatr* 21:1233-1240, 2014
  131. Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou E, Emberton M, Fitzpatrick JM, Heidenreich A, Hughes S, Joniau S, Kattan M, Mottet N, Oudard S, Payne H, Saad F, Sugihara T: Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. *Lancet Oncol* 15:e404-e414, 2014
  132. Droz JP, Medioni J, Chevreau C, De Mont-Serrat H, Merger M, Stopfer P, Kaiser R, Oudard S: Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel. *Anticancer Drugs* 25:1081-1088, 2014
  133. du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P: Incorporation of pazopanib in maintenance therapy of ovarian cancer. *J Clin Oncol* 32:3374-3382, 2014
  134. Dubruc E, Balme B, Dijoud F, Disant F, Thomas L, Wang Q, Pissaloux D, de la Fouchardiere A: Mutated and amplified NRAS in a subset of cutaneous melanocytic lesions with dermal spitzoid morphology: report of two pediatric cases located on the ear. *J Cutan Pathol* 41:866-872, 2014
  135. Duffaud F, Meeus P, Bachet JB, Cassier P, Huynh TK, Boucher E, Bouche O, Moutardier V, Le CA, Landi B, Marchal F, Bay JO, Bertucci F, Spano JP, Stoeckle E, Collard O, Chaigneau L, Isambert N, Lebrun-Ly V, Mancini J, Blay

- JY, Bonvalot S: Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG). *Eur J Surg Oncol* 40:1369-1375, 2014
136. Dufresne A, Alberti L, Brahmi M, Kabani S, Philippon H, Perol D, Blay JY: Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology. *BMC Cancer* 14:632, 2014
137. Dumont SN, Yang D, Dumont AG, Reynoso D, Blay JY, Trent JC: Targeted polytherapy in small cell sarcoma and its association with doxorubicin. *Mol Oncol* 8:1458-1468, 2014
138. Dumortier J, Decullier E, Hilleret MN, Bin-Dorel S, Valette PJ, Boillot O, Partensky C, Letoublon C, Ducerf C, Leroy V, Vuillez JP, Borson-Chazot F: Adjuvant Intraarterial Lipiodol or 131I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial. *J Nucl Med* 55:877-883, 2014
139. Dumortier J, Salame E, Roche B, Hurtova M, Conti F, Radenne S, Vanlemmens C, Pageaux GP, Saliba F, Samuel D, Compagnon P, Neau-Cransac M, Calmus Y, Guillaud O, Gugenheim J, Altieri M, Durand F, Hardwigsen J, Lorho R, Dharancy S, Leroy V, Di GF, Duvoux C: Severe fibrosis in patients with recurrent hepatitis C after liver transplantation: a French experience on 250 patients over 15 years (the Orfevre study). *Clin Res Hepatol Gastroenterol* 38:292-299, 2014
140. Dupinay T, Pounder KC, Ayrat F, Laaberki MH, Marston DA, Lacote S, Rey C, Barbet F, Voller K, Nazaret N, Artois M, Marianneau P, Lachuer J, Fooks AR, Pepin M, Legras-Lachuer C, McElhinney LM: Detection and genetic characterization of Seoul Virus from commensal brown rats in France. *Virol J* 11:32, 2014
141. Durack JC, Richioud B, Lyon J, Solomon SB: Late emergence of contrast-enhancing fat necrosis mimicking tumor seeding after renal cryoablation. *J Vasc Interv Radiol* 25:133-137, 2014
142. Durif-Bruckert C, Roux P, Morelle M, Mignotte H, Faure C, Moumjid-Ferdjaoui N: Shared decision-making in medical encounters regarding breast cancer treatment: the contribution of methodological triangulation. *Eur J Cancer Care (Engl)* 24:461-472, 2015
143. Dutertre M, Chakrama FZ, Combe E, Desmet FO, Mortada H, Polay EM, Gratadou L, Auboeuf D: A recently evolved class of alternative 3'-terminal exons involved in cell cycle regulation by topoisomerase inhibitors. *Nat Commun* 5:3395, 2014



144. Dutour A, Josserand V, Jury D, Guillermet S, Decouvelaere AV, Chotel F, Pointecouteau T, Rizo P, Coll JL, Blay JY: Targeted imaging of alpha(v)beta(3) expressing sarcoma tumor cells in vivo in pre-operative setting using near infrared: a potential tool to reduce incomplete surgical resection. *Bone* 62:71-78, 2014
145. Eberst L, Cropet C, Le CA, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Berard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, Ray-Coquard I: The off-label use of targeted therapies in sarcomas: the OUTC'S program. *BMC Cancer* 14:870, 2014
146. Edmond V, Dufour F, Poiroux G, Shoji K, Malleter M, Fouque A, Tauzin S, Rimokh R, Sergent O, Penna A, Dupuy A, Levade T, Theret N, Micheau O, Segui B, Legembre P: Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility. *Oncogene* 34:996-1005, 2015
147. El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M, Colombat P, Biron P, Tilly H, Pfreundschuh M, Cordonnier C, Sureda A, Cahn JY, Vernant JP, Gribben J, Cook G, Haynes AP, Ferrant A, Finel H, Montoto S, Dreger P: The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. *Ann Oncol* 25:2224-2229, 2014
148. Even C, Pautier P, Duvillard P, Floquet A, Kerbrat P, Troalen F, Rey A, Balleyguier C, Tazi Y, Leary A, Augereau P, Morice P, Droz JP, Fizazi K, Lhomme C: Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia. *Eur J Cancer* 50:2082-2089, 2014
149. Falewee MN, Schilf A, Boufflers E, Cartier C, Bachmann P, Pressoir M, Banal A, Michel C, Ettaiche M: Reduced infections with perioperative immunonutrition in head and neck cancer: exploratory results of a multicenter, prospective, randomized, double-blind study. *Clin Nutr* 33:776-784, 2014
150. Falk AT, Moureau-Zabotto L, Ouali M, Penel N, Italiano A, Bay JO, Olivier T, Sunyach MP, Boudou-Roquette P, Salas S, Le MC, Ducassou A, Isambert N, Kalbacher E, Pan C, Saada E, Bertucci F, Thyss A, Thariat J: Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. *Clin Oncol (R Coll Radiol)* 27:48-55, 2015
151. Fancello L, Monteil S, Popgeorgiev N, Rivet R, Gouriet F, Fournier PE, Raoult D, Desnues C: Viral communities associated with human pericardial fluids in idiopathic pericarditis. *PLoS One* 9:e93367, 2014

152. Fassi A, Schaerer J, Fernandes M, Riboldi M, Sarrut D, Baroni G: Tumor tracking method based on a deformable 4D CT breathing motion model driven by an external surface surrogate. *Int J Radiat Oncol Biol Phys* 88:182-188, 2014
153. Faure-Contier C: Tumoral markers in tumors of the pineal region. *Neurochirurgie* 61:143-145, 2015
154. Fayet Y, Chasles V, Ducimetiere F, Collard O, Berger C, Meeus P, Ranchere-Vince D, Thiesse P, Sunyach MP, Marec-Berard P, Poncet L, Cousin P, Blay JY, Ray-Coquard I: [To answer rare cancer issues. Geographical analysis of EMS sarcoma cohort in the Rhone-Alpes region]. *Bull Cancer* 101:127-136, 2014
155. Fayette J, Pointreau Y, Bourhis J, Lefebvre JL: [Squamous cell carcinoma of the hypopharynx and larynx: evidence-based care]. *Bull Cancer* 101:438-444, 2014
156. Ferlazzo ML, Sonzogni L, Granzotto A, Bodgi L, Lartin O, Devic C, Vogin G, Pereira S, Foray N: Mutations of the Huntington's disease protein impact on the ATM-dependent signaling and repair pathways of the radiation-induced DNA double-strand breaks: corrective effect of statins and bisphosphonates. *Mol Neurobiol* 49:1200-1211, 2014
157. Ferrari A, De Salvo GL, Brennan B, van Noesel MM, De PA, Casanova M, Francotte N, Kelsey A, Alaggio R, Oberlin O, Carli M, Ben-Arush M, Bergeron C, Merks JH, Jenney M, Stevens MC, Bisogno G, Orbach D: Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). *Ann Oncol* 26:567-572, 2015
158. Fizazi K, Pagliaro L, Laplanche A, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S: Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. *Lancet Oncol* 15:1442-1450, 2014
159. Foray N, Badie C, Alsbeih G, Lambin P, Geara F, Taghian AG, Deschavanne P, Gueulette J, Courdi A, Chavaudra N, Fertil B: Edmond-philippe malaise (1930-2013): a lifetime of perseverance leads to the cellular definition of intrinsic radiosensitivity. *Int J Radiat Oncol Biol Phys* 88:1215-1217, 2014
160. Foucaut AM, Berthouze SE, Touillaud M, Morelle M, Bourne-Branch, Kempf-Lepine AS, Carretier J, Perol D, Tredan O, Bachmann P, Fervers B: Deterioration of Physical Activity Level and Metabolic Risk Factors After Early-Stage Breast Cancer Diagnosis. *Cancer Nurs* 2014
161. Francois E, Azria D, Gourgou-Bourgade S, Jarlier M, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Seitz JF, Conroy T, Juzyna B, Gerard JP: Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy. *Radiother Oncol* 110:144-149, 2014

162. Frappaz D, Conter CF, Szathmari A, Valsijevic A, Mottolese C: The management of pineal tumors as a model for a multidisciplinary approach in neuro-oncology. *Neurochirurgie* 61:208-211, 2015
163. Frezza AM, Benson C, Judson IR, Litiere S, Marreaud S, Sleijfer S, Blay JY, Dewji R, Fisher C, van der Graaf W, Hayward L: Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. *Clin Sarcoma Res* 4:7, 2014
164. Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P: Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract. *Int J Gynecol Cancer* 24:S78-S82, 2014
165. Fruchart C, Tilly H, Morschhauser F, Ghesquieres H, Bouteloup M, Ferme C, Van Den Neste E, Bordessoule D, Bouabdallah R, Delmer A, Casasnovas RO, Ysebaert L, Ciappuccini R, Briere J, Gisselbrecht C: Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. *Biol Blood Marrow Transplant* 20:1905-1911, 2014
166. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fucikova J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jager D, Kalinski P, Karre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautes-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G: Classification of current anticancer immunotherapies. *Oncotarget* 5:12472-12508, 2014
167. Galmarini CM, Tredan O, Galmarini FC: Concomitant resistance and early-breast cancer: should we change treatment strategies? *Cancer Metastasis Rev* 33:271-283, 2014
168. Gao S, Bajrami I, Verrill C, Kigozi A, Ouaret D, Aleksic T, Asher R, Han C, Allen P, Bailey D, Feller S, Kashima T, Athanasou N, Blay JY, Schmitz S, Machiels JP, Upile N, Jones TM, Thalmann G, Ashraf SQ, Wilding JL, Bodmer WF, Middleton MR, Ashworth A, Lord CJ, Macaulay VM: Dsh homolog DVL3 mediates resistance to IGF1R inhibition by regulating IGF-RAS signaling. *Cancer Res* 74:5866-5877, 2014

169. Gao Y, Duran S, Lydon JP, DeMayo FJ, Burghardt RC, Bayless KJ, Bartholin L, Li Q: Constitutive activation of transforming growth factor Beta receptor 1 in the mouse uterus impairs uterine morphology and function. *Biol Reprod* 92:34, 2015
170. Gelderblom H, Blay JY, Seddon BM, Leahy M, Ray-Coquard I, Sleijfer S, Kerst JM, Rutkowski P, Bauer S, Ouali M, Marreaud S, van der Straaten RJ, Guchelaar HJ, Weitman SD, Hogendoorn PC, Hohenberger P: Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. *Eur J Cancer* 50:388-396, 2014
171. Gerfaud-Valentin M, Hot A, Huissoud C, Durieu I, Broussolle C, Seve P: Adult-onset Still's disease and pregnancy: about ten cases and review of the literature. *Rheumatol Int* 34:867-871, 2014
172. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P: Adult-onset Still's disease. *Autoimmun Rev* 13:708-722, 2014
173. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, Broussolle C, Seve P: Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. *Medicine (Baltimore)* 93:91-99, 2014
174. Gerfaud-Valentin M, Seve P, Hot A, Broussolle C, Jamilloux Y: Pathophysiology, subtypes, and treatments of adult-onset Still's disease: An update. *Rev Med Interne* 2014
175. Gerfaud-Valentin M, Seve P, Iwaz J, Gagnard A, Broussolle C, Durieu I, Ninet J, Hot A: Myocarditis in adult-onset still disease. *Medicine (Baltimore)* 93:280-289, 2014
176. Ghesquieres H: Pneumonitis following immunochemotherapy with rituximab: a new well-designed retrospective study to better assess the risks. *Leuk Lymphoma* 56:1577-1578, 2015
177. Gibert B, Delloye-Bourgeois C, Gattolliat CH, Meurette O, Le GS, Fombonne J, Ducarouge B, Lavial F, Bouhallier F, Creveaux M, Negulescu AM, Benard J, Janoueix-Lerosey I, Harel-Bellan A, Delattre O, Mehlen P: Regulation by miR181 family of the dependence receptor CDON tumor suppressive activity in neuroblastoma. *J Natl Cancer Inst* 106: 2014
178. Gilis L, Morisset S, Billaud G, Ducastelle-Lepretre S, Labussiere-Wallet H, Nicolini FE, Barraco F, Detrait M, Thomas X, Tedone N, Sobh M, Chidiac C, Ferry T, Salles G, Michallet M, Ader F: High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 49:664-670, 2014

179. Girard CA, Seitz-Polski B, Dolla G, Augert A, Vindrieux D, Bernard D, Lambeau G: [New physiopathological roles for the PLA2R1 receptor in cancer and membranous nephropathy]. *Med Sci (Paris)* 30:519-525, 2014
180. Gitenay D, Lallet-Daher H, Bernard D: Caspase-2 regulates oncogene-induced senescence. *Oncotarget* 5:5845-5847, 2014
181. Gitenay D, Wiel C, Lallet-Daher H, Vindrieux D, Aubert S, Payen L, Simonnet H, Bernard D: Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence. *Cell Death Dis* 5:e1089, 2014
182. Gnemmi V, Bouillez A, Gaudelot K, Hemon B, Ringot B, Pottier N, Glowacki F, Villers A, Vindrieux D, Cauffiez C, Van S, I, Bernard D, Leroy X, Aubert S, Perrais M: MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/beta-catenin pathway and interaction with SNAIL promoter. *Cancer Lett* 346:225-236, 2014
183. Gondeau C, Briolotti P, Razafy F, Duret C, Rubbo PA, Helle F, Reme T, Ripault MP, Ducos J, Fabre JM, Ramos J, Pecheur EI, Larrey D, Maurel P, Daujat-Chavanieu M: In vitro infection of primary human hepatocytes by HCV-positive sera: insights on a highly relevant model. *Gut* 63:1490-1500, 2014
184. Gourley C, Farley J, Provencher DM, Pignata S, Mileskin L, Harter P, Maenpaa J, Kim JW, Pujade-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D: Gynecologic Cancer InterGroup (GCIg) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. *Int J Gynecol Cancer* 24:S9-13, 2014
185. Graepi-Dulac J, Vlaeminck-Guillem V, Perier-Muzet M, Dalle S, Orgiazzi J: Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis. *Eur J Endocrinol* 170:R253-R262, 2014
186. Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, Maubec E, d'Incan M, Ram-Wolff C, Dalac S, Templier I, Esteve E, Quereux G, Machet L, Leduc M, Dereure O, Laroche L, Saiag P, Vergier B, Beylot-Barry M: Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. *JAMA Dermatol* 150:535-541, 2014
187. Gras B, Jacquaroud L, Wierinckx A, Lamblot C, Fauvet F, Lachuer J, Puisieux A, Ansieau S: Snail Family Members Unequally Trigger EMT and Thereby Differ in Their Ability to Promote the Neoplastic Transformation of Mammary Epithelial Cells. *PLoS One* 9:e92254, 2014
188. Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, Scoazec JY, Negrier S, Simonnet H, Pages G: The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. *Cancer Res* 74:873-883, 2014

189. Gronchi A, Colombo C, Le PC, Dei Tos AP, Le CA, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S: Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. *Ann Oncol* 25:578-583, 2014
190. Grothey A, George S, van CE, Blay JY, Sobrero A, Demetri GD: Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. *Oncologist* 19:669-680, 2014
191. Guenne C, Fayette J, Cosmidis A, Fuchsmann C, Tartas S, Favrel V, Ceruse P: Curative treatment can be an option for patients with metastatic squamous cell cancer of the head and neck. *Drug Des Devel Ther* 8:2549-2553, 2014
192. Guey B, Bodnar M, Manie SN, Tardivel A, Petrilli V: Caspase-1 autoproteolysis is differentially required for NLRP1b and NLRP3 inflammasome function. *Proc Natl Acad Sci U S A* 111:17254-17259, 2014
193. Guillaud O, Dumortier J, Sobesky R, Debray D, Wolf P, Vanlemmens C, Durand F, Calmus Y, Duvoux C, Dharancy S, Kamar N, Boudjema K, Bernard PH, Pageaux GP, Salame E, Gugenheim J, Lachaux A, Habes D, Radenne S, Hardwigsen J, Chazouilleres O, Trocetto JM, Woimant F, Ichai P, Branchereau S, Soubrane O, Castaing D, Jacquemin E, Samuel D, Duclos-Vallee JC: Long term results of liver transplantation for Wilson's disease: experience in France. *J Hepatol* 60:579-589, 2014
194. Guillot C, Favaudon V, Herceg Z, Sagne C, Sauvaigo S, Merle P, Hall J, Chemin I: PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models. *BMC Cancer* 14:603, 2014
195. Guillot C, Hall J, Herceg Z, Merle P, Chemin I: Update on hepatocellular carcinoma breakthroughs: poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategy. *Clin Res Hepatol Gastroenterol* 38:137-142, 2014
196. Guimier A, Ferrand S, Pierron G, Couturier J, Janoueix-Lerosey I, Combaret V, Mosseri V, Thebaud E, Gambart M, Plantaz D, Marabelle A, Coze C, Riolland X, Fasola S, Lapouble E, Freneaux P, Peuchmaur M, Michon J, Delattre O, Schleiermacher G: Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN. *PLoS One* 9:e101990, 2014
197. Gutierrez A, Pan L, Groen RW, Baleyrier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, Verplank L, An F, Burbank J, Norton S, Tolliday N, Steen H, Weng AP, Yuan H, Bradner JE, Mitsiades C, Look AT, Aster JC: Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. *J Clin Invest* 124:644-655, 2014

198. Haesebaert J, Lutringer-Magnin D, Kalecinski J, Barone G, Jacquard AC, Leocmach Y, Regnier V, Vanhems P, Chauvin F, Lasset C: Disparities of perceptions and practices related to cervical cancer prevention and the acceptability of HPV vaccination according to educational level in a French cross-sectional survey of 18-65 years old women. *PLoS One* 9:e109320, 2014
199. Hamelin-Peyron C, Vlaeminck-Guillem V, Haidous H, Schwall GP, Poznanovic S, Gorius-Gallet E, Michel S, Larue A, Guillotte M, Ruffion A, Choquet-Kastylevsky G, Ataman-Onal Y: Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability. *Clin Biochem* 47:901-908, 2014
200. Harris DG, Koo G, McCrone MP, Scalea TM, Chiu WC, Diaz JJ, Lissauer ME: Recurrent kidney injury in critically ill surgical patients is common and associated with worse outcomes. *J Trauma Acute Care Surg* 76:1397-1401, 2014
201. Harter PN, Zinke J, Scholz A, Tichy J, Zachskorn C, Kvasnicka HM, Goeppert B, Delloye-Bourgeois C, Hattingen E, Senft C, Steinbach JP, Plate KH, Mehlen P, Schulte D, Mittelbronn M: Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases. *PLoS One* 9:e92311, 2014
202. Hatu G, Bailly F, Pourcelot E, Pradat P, Miailhes P, Maynard M, Parant F, Chiarello P, Livrozet JM, Zoulim F, Gagnieu MC: Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients. *BMC Infect Dis* 14:150, 2014
203. Hayer J, Rodriguez C, Germanidis G, Deleage G, Zoulim F, Pawlotsky JM, Combet C: Ultradeep pyrosequencing and molecular modeling identify key structural features of hepatitis B virus RNase H, a putative target for antiviral intervention. *J Virol* 88:574-582, 2014
204. He J, Xiu L, De Porre P, Dass R, Thomas X: Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study. *Leuk Lymphoma* 1-10, 2014
205. Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, Karlin L, Hulin C, Gentil C, Guilhot F, Garderet L, Lamy T, Brechignac S, Pegourie B, Jaubert J, Dib M, Stoppa AM, Sebban C, Fohrer C, Fontan J, Fruchart C, Macro M, Orsini-Piocelle F, Lepeu G, Sohn C, Corre J, Facon T, Moreau P, Attal M, Avet-Loiseau H: Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. *Leukemia* 28:675-679, 2014
206. Heiblig M, Sobh M, Nicolini FE: Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives. *Leuk Res* 38:1145-1153, 2014

207. Heudel PE, Cousin P, Lurkin A, Cropet C, Ducimetiere F, Collard O, De Laroche G, Biron P, Meeus P, Thiesse P, Bergeron C, Vaz G, Mithieux F, Farsi F, Fayet Y, Gilly FN, Cellier D, Blay JY, Ray-Coquard I: Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhone-Alpes region. *Int J Clin Oncol* 19:744-752, 2014
208. Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De L, V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di M, V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP: Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. *Gastroenterology* 147:132-142, 2014
209. Hitier M, Ho Quoc C, La Marca S, Hamou C, Delay E: [Tolerance and efficacy of lipomodelling as an element of breast symmetry in breast reconstruction]. *Ann Chir Plast Esthet* 59:311-319, 2014
210. Ho Quoc C, Faure C, Carrabin N, Istasse F, Rivoire M, Delay E: [Glandular posterior flap of the breast for oncoplastic surgery]. *J Gynecol Obstet Biol Reprod (Paris)* 44:510-515, 2015
211. Ho Quoc C, Piat JM, Michel G, Dlimi C, La MS, Delay E: [Fat grafting to improve severe tuberous breast]. *J Gynecol Obstet Biol Reprod (Paris)* 44:503-509, 2015
212. Hock AK, Vigneron AM, Vousden KH: Ubiquitin-specific Peptidase 42 (USP42) Functions to Deubiquitylate Histones and Regulate Transcriptional Activity. *J Biol Chem* 289:34862-34870, 2014
213. Hoelt P, Dalle S, Thomas L: Cutaneous metastases of melanoma. *Ann Dermatol Venereol* 141:640-642, 2014
214. Hosel M, Lucifora J, Michler T, Holz G, Gruffaz M, Stahnke S, Zoulim F, Durantel D, Heikenwalder M, Nierhoff D, Millet R, Salvetti A, Protzer U, Buning H: Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction in vitro and in vivo. *Hepatology* 59:2110-2120, 2014
215. Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, Gourin MP, Recher C, Cahn JY, Ifrah N, Dombret H, Boissel N: Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. *Blood* 124:1312-1319, 2014
216. Houvenaeghel G, Classe JM, Garbay JR, Giard S, Cohen M, Faure C, Helene C, Belichard C, Uzan S, Hudry D, Azuar P, Villet R, Penault LF, Tunon de LC,



- Goncalves A, Esterni B: Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multicenter cohort study. *Breast* 23:561-566, 2014
217. Huynh TK, Meeus P, Cassier P, Bouche O, Lardiere-Deguelte S, Adenis A, Andre T, Mancini J, Collard O, Montemurro M, Bompas E, Rios M, Isambert N, Cupissol D, Blay JY, Duffaud F: Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. *BMC Cancer* 14:156, 2014
218. Isambert N, Ray-Coquard I, Italiano A, Rios M, Kerbrat P, Gauthier M, Blouet A, Chaigneau L, Duffaud F, Piperno-Neumann S, Kurtz JE, Girard N, Collard O, Bompas E, Penel N, Bay JO, Guillemet C, Collin F, Blay JY, Le CA, Thariat J: Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. *Eur J Cancer* 50:128-136, 2014
219. Jamilloux Y, Kodjikian L, Broussolle C, Seve P: Sarcoidosis and uveitis. *Autoimmun Rev* 13:840-849, 2014
220. Jamilloux Y, Neel A, Lecouffe-Desprets M, Fevre A, Kerever S, Guillon B, Bouvry D, Varron L, Redares C, Dominique S, Roux M, Chapelon-Abric C, Valeyre D, Ducray F, Bernard C, Broussolle C, Hamidou M, Seve P: Progressive multifocal leukoencephalopathy in patients with sarcoidosis. *Neurology* 82:1307-1313, 2014
221. Jamilloux Y, Seve P, Henry T: Inflammasomes in human diseases. *Rev Med Interne* 35:730-741, 2014
222. Jenkins MA, Dowty JG, Ait OD, Mathews JD, Hopper JL, Drouet Y, Lasset C, Bonadona V, Win AK: Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. *J Clin Oncol* 33:326-331, 2015
223. Jerusalem G, Bachelot T, Barrios C, Neven P, Di LA, Janni W, de BR: A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. *Cancer Treat Rev* 41:94-104, 2015
224. Jiang X, Cao Y, Li F, Su Y, Li Y, Peng Y, Cheng Y, Zhang C, Wang W, Ning G: Targeting beta-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours. *Nat Commun* 5:5809, 2014
225. Jobard E, Pontoizeau C, Blaise BJ, Bachelot T, Elena-Herrmann B, Tredan O: A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. *Cancer Lett* 343:33-41, 2014
226. Jones RL, Ferrari S, Blay JY, Navid F, Lardelli P, Alfaro V, Sigüero M, Soman N, Chawla SP: A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. *Invest New Drugs* 32:171-177, 2014

227. Jordheim LP, Cros-Perrial E, Matera EL, Bouledrak K, Dumontet C: Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability. *Clin Exp Pharmacol Physiol* 41:817-824, 2014
228. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litiere S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT: Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. *Lancet Oncol* 15:415-423, 2014
229. Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N, Vignon-Pennamen MD, Costes-Martineau V, Lamant L, Dalac S, Delattre C, Dechelotte P, Courville P, Carlotti A, de MA, Fraitag S, Levy A, Mitchell A, Petrella T: Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. *Am J Surg Pathol* 38:673-680, 2014
230. Julian-Reynier C, Resseguier N, Bouhnik AD, Eisinger F, Lasset C, Fourme E, Nogues C: Cigarette smoking in women after BRCA1/2 genetic test disclosure: a 5-year follow-up study of the GENEPSO PS cohort. *Genet Med* 17:117-124, 2015
231. Karam M, Thenoz M, Capraro V, Robin JP, Pinatel C, Lancon A, Galia P, Sibon D, Thomas X, Ducastelle-Lepretre S, Nicolini F, El-Hamri M, Chelghoun Y, Wattel E, Mortreux F: Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias. *Neoplasia* 16:21-30, 2014
232. Kay A, Melo da SE, Pedreira H, Negreiros S, Lobato C, Braga W, Muwonge R, Deny P, Reis M, Zoulim F, Trepo C, D'Oliveira A, Jr., Salcedo JM, Schinoni MI, Parana R: HBV/HDV co-infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers. *J Viral Hepat* 21:921-924, 2014
233. Kfoury A, Virard F, Renno T, Coste I: Dual function of MyD88 in inflammation and oncogenesis: implications for therapeutic intervention. *Curr Opin Oncol* 26:86-91, 2014
234. Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, Trepo C, Chemin I, Benjelloun S: Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma. *Liver Int* 34:e144-e150, 2014
235. Koffi J, Egounlety R, Pradat P, Lebosse F, Si-Ahmed SN, Lussier V, Chevallier P, Bailly F, Zoulim F: Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B. *Eur J Gastroenterol Hepatol* 26:146-154, 2014
236. Kramar A, Bachelot T, Madrange N, Pierga JY, Kerbrat P, Espie M, Fumoleau P, Pauporte I, Khayat D, Romieu G, Pivot X: Trastuzumab duration effects within

- patient prognostic subgroups in the PHARE trial. *Ann Oncol* 25:1563-1570, 2014
237. La Marca S, Toussoun G, Ho QC, Sebban H, Delay E: Pyoderma gangrenosum: an exceptional complication of venous access device. *J Vasc Access* 15:321-324, 2014
  238. Ladsous M, Vlaeminck-Guillem V, Dumur V, Vincent C, Dubrulle F, Dhaenens CM, Wemeau JL: Analysis of the thyroid phenotype in 42 patients with Pendred syndrome and nonsyndromic enlargement of the vestibular aqueduct. *Thyroid* 24:639-648, 2014
  239. Lafond C, Gassa F, Odin C, Drean G, Even J, De CR, Pommier P, Manens JP, Biston MC: Comparison between two treatment planning systems for volumetric modulated arc therapy optimization for prostate cancer. *Phys Med* 30:2-9, 2014
  240. Laouenan C, Marcellin P, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hezode C, Carrat F, Nicot F, Peytavin G, Mentre F, Guedj J: Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients. *Antimicrob Agents Chemother* 58:5332-5341, 2014
  241. Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Coiffier B, Benastou B, Koscielny S: Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study. *Invest Radiol* 49:794-800, 2014
  242. Lasset C, Kalecinski J, Regnier V, Barone G, Leocmach Y, Vanhems P, Chauvin F, Lutringer-Magnin D: Practices and opinions regarding HPV vaccination among French general practitioners: evaluation through two cross-sectional studies in 2007 and 2010. *Int J Public Health* 59:519-528, 2014
  243. Laurain A, de LA, Gincul R, Vanbiervliet G, Bramli S, Heyries L, Martane G, Amrani N, Serraj I, Saurin JC, Borentain P, Filoche B, Duburque C, Gaudric M, Sogni P, Dumortier J: Oesophageal capsule endoscopy versus oesophago-gastroduodenoscopy for the diagnosis of recurrent varices: a prospective multicentre study. *Dig Liver Dis* 46:535-540, 2014
  244. Lavelle C, Foray N: Chromatin structure and radiation-induced DNA damage: From structural biology to radiobiology. *Int J Biochem Cell Biol* 49C:84-97, 2014
  245. Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van CF, Rutkowski P, Van HR, Verweij J, Bonvalot S, Steward WP, Gronchi A,

- Hogendoorn PC, Litiere S, Marreaud S, Blay JY, van der Graaf WT: Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. *Ann Oncol* 25:2425-2432, 2014
246. Le Cornet C, Lortet-Tieulent J, Forman D, Beranger R, Flechon A, Fervers B, Schuz J, Bray F: Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data. *Eur J Cancer* 50:831-839, 2014
247. Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, Le TG, Michon J, Ladenstein R, Marec-Berard P, van den Berg H, Hjorth L, Wheatley K, Judson I, Juergens H, Craft A, Oberlin O, Dirksen U: Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. *J Clin Oncol* 32:2440-2448, 2014
248. Le Guen R, Madelaine I, Tournamille JF, Bellanger A, Astier A, Braguer D, Ollivier C, Bardin C, Lemare F, Daouphars M, Pinguet F, Latour JF, Vigneron J, Tilleul P: [Study impact: Descriptive analysis of pharmacist's clinical practice in onco-hematology]. *Ann Pharm Fr* 73:223-228, 2015
249. Le Guellec S, Chibon F, Ouali M, Perot G, Decouvelaere AV, Robin YM, Larousserie F, Terrier P, Coindre JM, Neuville A: Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas? *Am J Surg Pathol* 38:293-304, 2014
250. Le Jeune C, Bertoli S, Elhamri M, Vergez F, Borel C, Huguet F, Michallet M, Dumontet C, Recher C, Thomas X: Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. *Leuk Lymphoma* 55:855-862, 2014
251. Le Jeune C, Thomas X: Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. *Eur J Haematol* 2014
252. Le Moigne F., Boussel L, Haquin A, Bancel B, Ducerf C, Berthezene Y, Rode A: Grading of small hepatocellular carcinomas ( $\leq 2$  cm): correlation between histology, T2 and diffusion-weighted imaging. *Br J Radiol* 87:20130763, 2014
253. Le Tourneau C, Paoletti X, Servant N, Bieche I, Gentien D, Rio FT, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La RP, Escalup L, Mitry E, Tredan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavaille C, Kamal M: Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. *Br J Cancer* 111:17-24, 2014

254. Leal C, Le RK, Rahmi A, Varron L, Broussolle C, Denis P, Kodjikian L, Seve P: [Scleritis, clinical features, etiologies and treatment: a case series of 32 patients. *Rev Med Interne* 35:491-497, 2014
255. Leccia F, Del VL, Mariotti E, Di NR, Morel AP, Puisieux A, Salvatore F, Ansieau S: ABCG2, a novel antigen to sort luminal progenitors of B. *Mol Cancer* 13:213, 2014
256. Leccia MT, Planchamp F, Sassolas B, Combemale P, Modiano P, Bedane C, Cupissol D, Derrey S, Dygai-Cochet I, Lamant L, Lubrano V, Mirabel X, Mourregot A, Rouge Bugat ME, Siegrist S, Thariat J, Tiffet O, Truc G, Verdoni L, Mazeau-Woynar V: [Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute]. *Ann Dermatol Venereol* 141:111-121, 2014
257. Ledermann JA, Ray-Coquard I: Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges. *Am Soc Clin Oncol Educ Booke* 282-e286, 2014
258. Lefaucheur R, Ahtoy P, Bouwyn JP, Maltete D, Bourre B: Progressive multifocal leukoencephalopathy in patients with sarcoidosis. *Neurology* 83:1301-1302, 2014
259. Lefevre A, Thomas L, Dalle S: Negative pigment network. *Ann Dermatol Venereol* 141:237-238, 2014
260. Lefranc M, Derrey S, Merle P, Tir M, Constans JM, Montpellier D, Macron JM, Gars DL, Peltier J, Baledent O, Krystkowiak P: High-resolution Three-dimensional T2 Star Weighted Angiography (HR 3-D SWAN): An Optimized 3T MRI Sequence for Targeting the Subthalamic Nucleus. *Neurosurgery* 2014
261. Lefranc M, Manto M, Merle P, Tir M, Montpellier D, Constant JM, Le GD, Macron JM, Krystkowiak P: Targeting the red nucleus for cerebellar tremor. *Cerebellum* 13:372-377, 2014
262. Legeay AL, Thomas L, Dalle S: Subungual melanoma. *Ann Dermatol Venereol* 141:69-70, 2014
263. Leone V, Langella C, D'Angelo D, Mussnich P, Wierinckx A, Terracciano L, Raverot G, Lachuer J, Rotondi S, Jaffrain-Rea ML, Trouillas J, Fusco A: Mir-23b and miR-130b expression is downregulated in pituitary adenomas. *Mol Cell Endocrinol* 390:1-7, 2014
264. Leporq B, Saint-Jalmes H, Rabrait C, Pilleul F, Guillaud O, Dumortier J, Scoazec JY, Beuf O: Optimization of intra-voxel incoherent motion imaging at 3.0 Tesla for fast liver examination. *J Magn Reson Imaging* 2014

265. Levy C, Allouache D, Lacroix J, Dugue AE, Supiot S, Campone M, Mahe M, Kichou S, Leheurteur M, Hanzen C, Dieras V, Kirova Y, Campana F, Le RE, Gras L, Bachelot T, Sunyach MP, Hrab I, Geffreot J, Gunzer K, Constans JM, Grellard JM, Clarisse B, Paoletti X: REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. *Ann Oncol* 25:2351-2356, 2014
266. Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, Gallazzini M, Olson EN, Lam H, Henske EP, Dong Z, Apte U, Pallet N, Johnson RL, Terzi F, Kwiatkowski DJ, Scoazec JY, Martignoni G, Pende M: Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. *J Exp Med* 211:2249-2263, 2014
267. Lin SH, Wang J, Saintigny P, Wu CC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV: Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. *BMC Genomics* 15:1079, 2014
268. Lubrano V, Derrey S, Truc G, Mirabel X, Thariat J, Cupissol D, Sassolas B, Combemale P, Modiano P, Bedane C, Dygai-Cochet I, Lamant L, Mourregot A, Rouge Bugat ME, Siegrist S, Tiffet O, Mazeau-Woynar V, Verdoni L, Planchamp F, Leccia MT: [Locoregional treatments of brain metastases for patients with metastatic cutaneous melanoma: French national guidelines]. *Neurochirurgie* 60:269-275, 2014
269. Lucifora J, Xia Y, Reisinger F, Stadler D, Heikenwalder M, Protzer U: [Specific degradation of nuclear hepatitis B virus covalently closed circular DNA]. *Med Sci (Paris)* 30:724-726, 2014
270. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Huser N, Durantel D, Liang TJ, Munk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U: Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. *Science* 343:1221-1228, 2014
271. Machon C, Jordheim LP, Puy JY, Lefebvre I, Dumontet C, Guitton J: Fully validated assay for the quantification of endogenous nucleoside mono- and triphosphates using online extraction coupled with liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem* 406:2925-2941, 2014
272. Machon C, Le CB, Coste S, Riviere M, Payen L, Bernard D, Guitton J: Quantification of beta-aminopropionitrile, an inhibitor of lysyl oxidase activity, in plasma and tumor of mice by liquid chromatography tandem mass spectrometry. *Biomed Chromatogr* 28:1017-1023, 2014

273. Maillet D, Goulvent T, Rimokh R, Vacher-Lavenu MC, Pautier P, Alexandre J, Pujade-Laurraine E, Devouassoux-Shisheboran M, Treilleux I, Ray-Coquard I, Savina A: Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network. *Gynecol Oncol* 132:181-187, 2014
274. Maillet L, Chopin N, Treilleux I, Bachelot T, Tredan O, Faure C, Caux C, Beurrier F: [Spontaneous regression of breast cancer after biopsy. About two cases]. *Gynecol Obstet Fertil* 42:269-272, 2014
275. Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardiere C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, Andre T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF: Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. *Lancet Oncol* 15:819-828, 2014
276. Mallinjoind P, Villemin JP, Mortada H, Polay EM, Desmet FO, Samaan S, Chautard E, Tranchevent LC, Auboeuf D: Endothelial, epithelial, and fibroblast cells exhibit specific splicing programs independently of their tissue of origin. *Genome Res* 24:511-521, 2014
277. Malouf GG, Job S, Paradis V, Fabre M, Brugieres L, Saintigny P, Vescovo L, Belghiti J, Branchereau S, Faivre S, de RA, Raymond E: Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. *Hepatology* 59:2228-2237, 2014
278. Manie SN, Lebeau J, Chevet E: Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 3. Orchestrating the unfolded protein response in oncogenesis: an update. *Am J Physiol Cell Physiol* 307:C901-C907, 2014
279. Marabelle A, Kohrt H, Caux C, Levy R: Intratumoral immunization: a new paradigm for cancer therapy. *Clin Cancer Res* 20:1747-1756, 2014
280. Marcel V, Catez F, Mertani HC, Diaz JJ: [The ribosome: a new player in tumorigenesis?]. *Med Sci (Paris)* 30:21-24, 2014
281. Martinez-Diez M, Guillen-Navarro MJ, Pera B, Bouchet BP, Martinez-Leal JF, Barasoain I, Cuevas C, Andreu JM, Garcia-Fernandez LF, Diaz JF, Aviles P, Galmarini CM: PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. *Biochem Pharmacol* 88:291-302, 2014
282. Martino A, Campa D, Jurczynski A, Martinez-Lopez J, Moreno MJ, Varkonyi J, Dumontet C, Garcia-Sanz R, Gemignani F, Jamrozik K, Stepiel A, Jacobsen SE, Andersen V, Jurado M, Landi S, Rossi AM, Lesueur F, Marques H, Dudzilski M,

- Watek M, Moreno V, Orciuolo E, Petrini M, Reis RM, Rios R, Sainz J, Vogel U, Buda G, Vangsted AJ, Canzian F: Genetic variants and multiple myeloma risk: IMMENSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. *Cancer Epidemiol Biomarkers Prev* 23:670-674, 2014
283. Maurer MJ, Ghesquieres H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo MT, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR: Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. *J Clin Oncol* 32:1066-1073, 2014
284. McCarron MJ, Marie JC: TGF-beta prevents T follicular helper cell accumulation and B cell autoreactivity. *J Clin Invest* 124:4375-4386, 2014
285. Mehlen P, Tauszig-Delamasure S: Dependence receptors and colorectal cancer. *Gut* 63:1821-1829, 2014
286. Mendes-da-Cruz DA, Brignier AC, Asnafi V, Baleyrier F, Messias CV, Lepelletier Y, Bedjaoui N, Renand A, Smaniotto S, Canioni D, Milpied P, Balabanian K, Bousso P, Lepretre S, Bertrand Y, Dombret H, Ifrah N, Dardenne M, Macintyre E, Savino W, Hermine O: Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors. *PLoS One* 9:e103405, 2014
287. Merindol N, Riquet A, Szablewski V, Eliaou JF, Puisieux A, Bonnefoy N: The emerging role of Twist proteins in hematopoietic cells and hematological malignancies. *Blood Cancer J* 4:e206, 2014
288. Meurillon M, Marton Z, Hospital A, Jordheim LP, Bejaud J, Lionne C, Dumontet C, Perigaud C, Chaloin L, Peyrottes S: Structure-activity relationships of beta-hydroxyphosphonate nucleoside analogues as cytosolic 5'-nucleotidase II potential inhibitors: synthesis, in vitro evaluation and molecular modeling studies. *Eur J Med Chem* 77:18-37, 2014
289. Meyer V, Flechon A, Tartas S, Fassi-Fehri H, Ruffion A, Martin X, Colombel M: [Impact of neoadjuvant chemotherapy on therapeutic management of muscle-invasive bladder cancer]. *Prog Urol* 25:83-89, 2015
290. Mialhes P, Maynard-Muet M, Lebosse F, Carrat F, Bouix C, Lascoux-Combe C, Sogni P, Rey D, Barthe Y, Pol S, Cacoub P, Zoulim F, Piroth L: Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. *J Hepatol* 61:761-769, 2014
291. Michallet M, Sobh M, Serrier C, Morisset S, Labussiere H, Ducastelle S, Barraco F, Gilis L, Thomas X, Nicolini FE: Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen



- unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings. *Leuk Lymphoma* 1-5, 2014
292. Mohkam K, Belkhir L, Wallon M, Darnis B, Peyron F, Ducerf C, Gigot JF, Mabrut JY: Surgical management of liver hydatid disease: subadventitial cystectomy versus resection of the protruding dome. *World J Surg* 38:2113-2121, 2014
  293. Mohkam K, Ledochowski S, Ducerf C, Mabrut JY: Intraoperative Identification of Biliocystic Communication Could be the Key to Avoiding Postoperative Complications Independent of the Adopted Surgical Technique to Treat Hydatid Cysts: Reply. *World J Surg* 2014
  294. Mollereau B, Manie S, Napoletano F: Getting the better of ER stress. *J Cell Commun Signal* 8:311-321, 2014
  295. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomme C, Richardson G, Rincon DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM: Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol* 15:799-808, 2014
  296. Mordant P, Deneuve S, Rivera C, Carrabin N, Mieog JS, Malyshev N, Van Der Vorst JR, Audisio RA: Quality of life of surgical oncology residents and fellows across Europe. *J Surg Educ* 71:222-228, 2014
  297. Moro-Sibilot D, Perol D, Chabaud S, Cadranel J, Audigier VC, Perol M: The TAILOR study: to agree or to disagree? *Lung Cancer* 84:315-316, 2014
  298. Mory C, Auvray V, Zhang B, Grass M, Schafer D, Chen SJ, Carroll JD, Rit S, Peyrin F, Douek P, Boussel L: Cardiac C-arm computed tomography using a 3D + time ROI reconstruction method with spatial and temporal regularization. *Med Phys* 41:021903, 2014
  299. Moussata D, Napoleon B, Lepilliez V, Klich A, Ecochard R, Lapalus MG, Nancey S, Cenni JC, Ponchon T, Chayvialle JA, Saurin JC: Endoscopic treatment of severe duodenal polyposis as an alternative to surgery for patients with familial adenomatous polyposis. *Gastrointest Endosc* 2014
  300. Moyret-Lalle C, Ruiz E, Puisieux A: Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer. *World J Clin Oncol* 5:311-322, 2014
  301. Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van P, I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor

- MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F: Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. *Ann Oncol* 25:1570-1577, 2014
302. Nait-Achour T., Sentis S, Teyssier C, Philippat A, Lucas A, Corbo L, Cavailles V, Jalaguier S: Transcriptional repression of estrogen receptor alpha signaling by SENP2 in breast cancer cells. *Mol Endocrinol* 28:183-196, 2014
303. Napoleon B, Gincul R, Ponchon T, Berthiller J, Escourrou J, Canard JM, Boyer J, Barthet M, Ponsot P, Laugier R, Helbert T, Coumaros D, Scoazec JY, Mion F, Saurin JC: Endoscopic papillectomy for early ampullary tumors: long-term results from a large multicenter prospective study. *Endoscopy* 46:127-134, 2014
304. Napoleon B, Lemaistre AI, Pujol B, Caillol F, Lucidarme D, Bourdariat R, Morellon-Mialhe B, Fumex F, Lefort C, Lepilliez V, Palazzo L, Monges G, Filoche B, Giovannini M: A novel approach to the diagnosis of pancreatic serous cystadenoma: needle-based confocal laser endomicroscopy. *Endoscopy* 47:26-32, 2015
305. Naro C, Barbagallo F, Chieffi P, Bourgeois CF, Paronetto MP, Sette C: The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival. *Nucleic Acids Res* 42:3218-3227, 2014
306. Negrier S, Bushmakina AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ: Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. *Eur J Cancer* 50:1766-1771, 2014
307. Nguyen F, Moumjid N, Charles C, Gafni A, Whelan T, Carrere MO: Treatment decision-making in the medical encounter: comparing the attitudes of French surgeons and their patients in breast cancer care. *Patient Educ Couns* 94:230-237, 2014
308. Nguyen NT, Vendrell JA, Poulard C, Gyorffy B, Goddard-Leon S, Bieche I, Corbo L, Le RM, Bachelot T, Treilleux I, Cohen PA: A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers. *Mol Oncol* 8:1441-1457, 2014
309. Nicolas-Virelizier E, Segura-Ferlay C, Ghesquieres H, Chassagne-Clement C, Gargi T, Biron P, Belhabri A, Rey P, Faurie P, Chabaud S, Sebban C: Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up. *Hematol Oncol* 33:1-8, 2015

310. Nozieres C, Zhang CX, Buffet A, Dupasquier S, Vargas-Poussou R, Guillaud-Bataille M, Cordier-Bussat M, Ruzsniowski P, Christin-Maitre S, Murat A, Groussin L, Vezzosi D, Cardot-Bauters C, Hervieu V, Joly MO, Giraud S, Odou MF, Gimenez-Roqueplo AP, Goudet P, Borson-Chazot F, Calender A: p.Ala541Thr variant of MEN1 gene: a non deleterious polymorphism or a pathogenic mutation? *Ann Endocrinol (Paris)* 75:133-140, 2014
311. Ohta T, Kim YH, Oh JE, Satomi K, Nonoguchi N, Keyvani K, Pierscianek D, Sure U, Mittelbronn M, Paulus W, Vital A, Yokoo H, McDonald K, Kleihues P, Nazaret N, Barbet F, Lachuer J, Ohgaki H: Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas. *J Neuropathol Exp Neurol* 73:908-915, 2014
312. Osorio A, Milne RL, Kuchenbaecker K, Vaclova T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Diez O, Ramon YC, Konstantopoulou I, Martinez-Bouzas C, Andres CR, Soucy P, McGuffog L, Barrowdale D, Lee A, Swe B, Arver B, Rantala J, Loman N, Ehrencrona H, Olopade OI, Beattie MS, Domchek SM, Nathanson K, Rebbeck TR, Arun BK, Karlan BY, Walsh C, Lester J, John EM, Whittemore AS, Daly MB, Southey M, Hopper J, Terry MB, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Hansen TV, Jonson L, Ejlersen B, Gerdes AM, Infante M, Herraes B, Moreno LT, Weitzel JN, Herzog J, Weeman K, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Bonanni B, Mariette F, Volorio S, Viel A, Varesco L, Papi L, Ottini L, Tibiletti MG, Radice P, Yannoukakos D, Garber J, Ellis S, Frost D, Platte R, Fineberg E, Evans G, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Eccles D, Cook J, Hodgson S, Brewer C, Tischkowitz M, Douglas F, Porteous M, Side L, Walker L, Morrison P, Donaldson A, Kennedy J, Foo C, Godwin AK, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Damiola F, Poppe B, Claes K, Piedmonte M, Tucker K, Backes F, Rodriguez G, Brewster W, Wakeley K, Rutherford T, Caldes T, Nevanlinna H, Aittomaki K, Rookus MA, van Os TA, van der Kolk L, de Lange JL, Meijers-Heijboer HE, van der Hout AH, van Asperen CJ, Gomez Garcia EB, Hoogerbrugge N, Collee JM, van Deurzen CH, van der Luijt RB, Devilee P, Hebon, Olah E, Lazaro C, Teule A, Menendez M, Jakubowska A, Cybulski C, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Johannsson OT, Maugard C, Montagna M, Tognazzo S, Teixeira MR, Healey S, Investigators K, Olsword C, Guidugli L, Lindor N, Slager S, Szabo CI, Vijai J, Robson M, Kauff N, Zhang L, Rau-Murthy R, Fink-Retter A, Singer CF, Rappaport C, Geschwantler KD, Pfeiler G, Tea MK, Berger A, Phelan CM, Greene MH, Mai PL, Lejbkowitz F, Andrulis I, Mulligan AM, Glendon G, Toland AE, Bojesen A, Pedersen IS, Sunde L, Thomassen M, Kruse TA, Jensen UB, Friedman E, Laitman Y, Shimon SP, Simard J, Easton DF, Offit K, Couch FJ, Chenevix-Trench G, Antoniou AC, Benitez J: DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genet* 10:e1004256, 2014

313. Pallure V, Frouin E, Petrella T, Depaepe L, Dalle S, Dereure O: Cutaneous indeterminate cell histiocytosis: two new observations including a case with paraneoplastic-like evolution. *Eur J Dermatol* 24:505-506, 2014
314. Pan H, Gazarian A, Fourier A, Gagnieu MC, Leveneur O, Sobh M, Michallet MC, Buff S, Roger T, Dubernard JM, Michallet M: Short-term pharmacokinetic study of mycophenolate mofetil in neonatal swine. *Transplant Proc* 46:3620-3628, 2014
315. Papo M, Bielefeld P, Vallet H, Seve P, Wechsler B, Cacoub P, Le HP, Papo T, Bodaghi B, Saadoun D: Tocilizumab in severe and refractory non-infectious uveitis. *Clin Exp Rheumatol* 32:S75-S79, 2014
316. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ: A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. *Cancer* 2014
317. Parent R, Durantel D, Lahlali T, Salle A, Plissonnier ML, DaCosta D, Lesca G, Zoulim F, Marion MJ, Bartosch B: An immortalized human liver endothelial sinusoidal cell line for the study of the pathobiology of the liver endothelium. *Biochem Biophys Res Commun* 450:7-12, 2014
318. Parent R, Plissonnier ML, Bancel B, Liao WL, Rumin S, Asaad R, Till M, Sanlaville D, Zoulim F, Trepo C, Marion MJ: Diversity of hepatocellular carcinoma clones bearing hematopoietic malignancies-related chromosomal translocation. *J Cell Biochem* 115:666-677, 2014
319. Parra D, Mekki Y, Durieu I, Broussolle C, Seve P: Clinical and biological manifestations in primary parvovirus B19 infection in immunocompetent adult: a retrospective study of 26 cases. *Rev Med Interne* 35:289-296, 2014
320. Pautier P, Nam EJ, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I: Gynecologic Cancer InterGroup (GCIg) consensus review for high-grade undifferentiated sarcomas of the uterus. *Int J Gynecol Cancer* 24:S73-S77, 2014
321. Payen L, Honorat M, Guitton J, Gauthier C, Bouard C, Lecerf-Schmidt F, Peres B, Terreux R, Gervot H, Rioufol C, Boumendjel A, Puisieux A, Di PA: MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts. *Oncotarget* 5:11957-11970, 2014
322. Pecheur EI: Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'? *Gut* 63:1035-1037, 2014

323. Pereira S, Malard V, Ravanat JL, Davin AH, Armengaud J, Foray N, Adam-Guillermín C: Low doses of gamma-irradiation induce an early bystander effect in zebrafish cells which is sufficient to radioprotect cells. *PLoS One* 9:e92974, 2014
324. Perier-Muzet M, Thomas L, Dalle S: Safety and management of new primary melanomas during receipt of BRAF inhibitors. *J Clin Oncol* 32:3202, 2014
325. Perier-Muzet M, Thomas L, Poulalhon N, Debarbieux S, Bringuier PP, Duru G, Depaepé L, Balme B, Dalle S: Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. *J Invest Dermatol* 134:1351-1358, 2014
326. Peron J, Polivka V, Chabaud S, Poupart M, Ceruse P, Ramade A, Girodet D, Zrounba P, Fayette J: An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents. *BMC Cancer* 14:504, 2014
327. Perriaud L, Lachuer J, Dante R: The "Methyl-CpG Binding Domain protein 2" plays a repressive role in relation to the promoter CpG content in the normal human cell line MRC5. *Curr Pharm Des* 20:1598-1603, 2014
328. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gomez Garcia EB, Olopade OI, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Karlan BY, Orsulic S, Lester J, Chung WK, Miron A, Southey MC, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Ding YC, Neuhausen SL, Hansen TV, Gerdes AM, Ejlersen B, Jonson L, Osorio A, Martinez-Bouzas C, Benitez J, Conway EE, Blazer KR, Weitzel JN, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Barile M, Ficarazzi F, Mariette F, Fortuzzi S, Viel A, Giannini G, Papi L, Martayan A, Tibiletti MG, Radice P, Vratimos A, Fostira F, Garber JE, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Davidson R, Hodgson SV, Ellis S, Cole T, Godwin AK, Claes K, Van MT, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Wappenschmidt B, Wang-Gohrke S, Bressac-de PB, Buecher B, Delnatte C, Houdayer C, Stoppa-Lyonnet D, Damiola F, Coupier I, Barjhoux L, Venat-Bouvet L, Golmard L, Boutry-Kryza N, Sinilnikova OM, Caron O, Pujol P, Mazoyer S, Belotti M, Piedmonte M, Friedlander ML, Rodriguez GC, Copeland LJ, de la Hoya M, Segura PP, Nevanlinna H, Aittomaki K, van Os TA, Meijers-Heijboer HE, van der Hout AH, Vreeswijk MP, Hoogerbrugge N, Ausems MG, van Doorn HC, Collee JM, Olah E, Diez O, Blanco I, Lazaro C, Brunet J, Feliubadalo L, Cybulski C, Gronwald J, Durda K, Jaworska-Bieniek K, Sukiennicki G, Arason A, Chiquette J, Teixeira

- MR, Olswold C, Couch FJ, Lindor NM, Wang X, Szabo CI, Offit K, Corines M, Jacobs L, Robson ME, Zhang L, Joseph V, Berger A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Glendon G, Tchatchou S, Andrulis IL, Toland AE, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Laitman Y, Rantala J, von WA, Ehrencrona H, Askmalm MS, Borg A, Kuchenbaecker KB, McGuffog L, Barrowdale D, Healey S, Lee A, Pharoah PD, Chenevix-Trench G, Antoniou AC, Friedman E: Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev* 24:308-316, 2015
329. Philip CA, Pautier P, Duffaud F, Ray-Coquard I: High-grade undifferentiated sarcomas of the uterus: diagnosis, outcomes, and new treatment approaches. *Curr Oncol Rep* 16:405, 2014
330. Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roche H, Bachelot T, Charafe-Jauffret E, Bonnetterre J, Hernandez J, Bidard FC, Viens P: Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. *Clin Cancer Res* 21:1298-1304, 2015
331. Pilati C, Letouze E, Nault JC, Imbeaud S, Boulai A, Calderaro J, Poussin K, Franconi A, Couchy G, Morcrette G, Mallet M, Taouji S, Balabaud C, Terris B, Canal F, Paradis V, Scoazec JY, de MA, Guettier C, Bioulac-Sage P, Chevet E, Calvo F, Zucman-Rossi J: Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. *Cancer Cell* 25:428-441, 2014
332. Pioche M, Vanbiervliet G, Jacob P, Duburque C, Gincul R, Filoche B, Daudet J, Filippi J, Saurin JC: Prospective randomized comparison between axial- and lateral-viewing capsule endoscopy systems in patients with obscure digestive bleeding. *Endoscopy* 46:479-484, 2014
333. Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Tigaud I, Michallet M, Dumontet C, Thomas X: Higher percentage of CD34 +. *Leuk Lymphoma* 1-8, 2014
334. Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Tigaud I, Michallet M, Dumontet C, Thomas X: HIGHER PERCENTAGE OF CD34CD38 CELLS DETECTED BY MULTI-PARAMETER FLOW CYTOMETRY FROM LEUKAPHERESIS PRODUCTS PREDICT UNSUSTAINED COMPLETE REMISSION IN AML. *Leuk Lymphoma* 1-17, 2014
335. Poulard C, Rambaud J, Hussein N, Corbo L, Le RM: JMJD6 regulates ERalpha methylation on arginine. *PLoS One* 9:e87982, 2014

336. Poulard C, Rambaud J, Le RM, Corbo L: Proximity ligation assay to detect and localize the interactions of ERalpha with PI3-K and Src in breast cancer cells and tumor samples. *Methods Mol Biol* 1204:135-143, 2014
337. Poveda A, Ray-Coquard I, Romero I, Lopez-Guerrero JA, Colombo N: Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin. *Cancer Treat Rev* 40:366-375, 2014
338. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C, Grippo PJ: TGF-beta: duality of function between tumor prevention and carcinogenesis. *J Natl Cancer Inst* 106:djt369, 2014
339. Prudent J, Gillet G, Popgeorgiev N: Nr2f1 but not zBcl-xL antagonizes Bcl-wav pro-apoptotic activity in zebrafish. *Commun Integr Biol* 7:e28008, 2014
340. Puisieux A, Brabletz T, Caramel J: Oncogenic roles of EMT-inducing transcription factors. *Nat Cell Biol* 16:488-494, 2014
341. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. *J Clin Oncol* 32:1302-1308, 2014
342. Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Ferme C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van IG, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol* 32:1188-1194, 2014
343. Rahme R, Thomas X, Recher C, Vey N, Delaunay J, Deconinck E, Hirsch P, Bordessoule D, Micol JB, Stamatoullas A, Mariette C, Pautas C, Bories P, Marolleau JP, Hunault-Berger M, Fegueux N, Raffoux E, Dombret H, Degos L, Fenaux P, Ades L: Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. *Leukemia* 28:2422-2424, 2014
344. Rahmi G, Samaha E, Vahedi K, Delvaux M, Gay G, Lamouliatte H, Filoche B, Saurin JC, Ponchon T, Rhun ML, Coumaros D, Bichard P, Maniere T, Lenain E, Chatellier G, Cellier C: Long-term follow-up of patients undergoing capsule and double-balloon enteroscopy for identification and treatment of small-bowel vascular lesions: a prospective, multicenter study. *Endoscopy* 46:591-597, 2014
345. Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzananza D, Colombo

- N: Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. *Int J Gynecol Cancer* 24:S42-S47, 2014
346. Renard C, Pissaloux D, Decouvelaere AV, Bourdeaut F, Ranchere D: Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors? *Cancer Genet* 207:384-389, 2014
347. Renard C, Ranchere-Vince D: [Ewing/PNET sarcoma family of tumors: towards a new paradigm?]. *Ann Pathol* 35:86-97, 2015
348. Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C: Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. *Leuk Lymphoma* 55:188-190, 2014
349. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klamann I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le TC, Delord JP, Levitsky H, Blay JY, Ruttinger D: Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. *Cancer Cell* 25:846-859, 2014
350. Rigaud J, Durand X, Camparo P, Avances C, Culine S, Sebe P, Flechon A, Murez T, Soulie M: Initial management of testicular cancer: practice survey among urologists and pathologists. *Clin Genitourin Cancer* 12:292-299, 2014
351. Rioufol C, Ranchon F, Schwiertz V, Vantard N, Joue E, Gourc C, Gauthier N, Guedat MG, Salles G, Souquet PJ, Favier B, Gilles L, Freyer G, You B, Trillet-Lenoir V, Guitton J: Administration of anticancer drugs: exposure in hospital nurses. *Clin Ther* 36:401-407, 2014
352. Rizzieri D, Vey N, Thomas X, Huguette-Rigal F, Schlenk RF, Krauter J, Kindler T, Gjertsen BT, Blau IW, Jacobsen TF, Johansen M, Bergeland T, Gianella-Borradori A, Krug U: A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. *Leuk Lymphoma* 55:2114-2119, 2014
353. Robine A, Hot A, Maucourt-Boulch D, Iwaz J, Broussolle C, Seve P: Fever of unknown origin in the 2000s: evaluation of 103 cases over eleven years. *Presse Med* 43:e233-e240, 2014
354. Roellinghoff F, Benilov A, Dauvergne D, Dedes G, Freud N, Janssens G, Krimmer J, Letang JM, Pinto M, Prieels D, Ray C, Smeets J, Stichelbaut F, Testa E: Real-time proton beam range monitoring by means of prompt-gamma detection with a collimated camera. *Phys Med Biol* 59:1327-1338, 2014
355. Roger C, Chikh K, Raverot V, Claustrat F, Borson-Chazot F, Bournaud-Salinas C, Charrie A: New-generation thyroglobulin assay: performance and implications



- for follow-up of differentiated thyroid carcinoma. *Ann Endocrinol (Paris)* 75:227-231, 2014
356. Roux S, Ferry T, Chidiac C, Bouaziz A, Ninet J, Perard L, Farhat F, Broussolle C, Seve P: Infectious thoracic aortic aneurysms: 7 cases and literature review. *Rev Med Interne* 35:357-364, 2014
  357. Ruffion A, Perrin P, Devonec M, Champetier D, Decaussin M, Paparel P, Vlaeminck-Guillem V: Additional value of PCA3 density to predict initial prostate biopsy outcome. *World J Urol* 32:917-923, 2014
  358. Ruiz AL, Soudja SM, Deceneux C, Lauvau G, Marie JC: NK1.1+ CD8+ T cells escape TGF-beta control and contribute to early microbial pathogen response. *Nat Commun* 5:5150, 2014
  359. Saison J, Berger F, Lebosse F, Audoual R, Thomas X, Michallet M: Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia. *Am J Case Rep* 15:13-17, 2014
  360. Salenave S, Ancelle D, Bahougne T, Raverot G, Kamenicky P, Bouligand J, Guiochon-Mantel A, Linglart A, Souchon PF, Nicolino M, Young J, Borson-Chazot F, Delemer B, Chanson P: Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. *J Clin Endocrinol Metab* 100:1177-1186, 2015
  361. Samaan S, Tranchevent LC, Dardenne E, Polay EM, Zonta E, Germann S, Gratadou L, Dutertre M, Auboeuf D: The Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathways. *Nucleic Acids Res* 42:2197-2207, 2014
  362. Samalin E, Bouche O, Thezenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissiere F, Laurent-Puig P, Ychou M, Mazard T: Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. *Br J Cancer* 110:1148-1154, 2014
  363. Sarrut D, Bardies M, Boussion N, Freud N, Jan S, Letang JM, Loudos G, Maigne L, Marcatili S, Mauxion T, Papadimitroulas P, Perrot Y, Pietrzyk U, Robert C, Schaart DR, Visvikis D, Buvat I: A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications. *Med Phys* 41:064301, 2014
  364. Sassolas B, Mourregot A, Thariat J, Tiffet O, Dygai-Cochet I, Mirabel X, Truc G, Cupissol D, Modiano P, Combemale P, Bedane C, Derrey S, Lamant L, Lubrano V, Siegrist S, Rouge-Bugat ME, Mazeau-Woynar V, Verdoni L, Planchamp F, Leccia MT: [Loco-regional treatments of the metastatic sites for patients with

- pauci-metastatic cutaneous melanoma (without brain metastasis): French national guidelines]. *Bull Cancer* 101:9-16, 2014
365. Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio FT, Pierron G, Lapouble E, Combaret V, Speleman F, de WB, Djos A, Ora I, Hedborg F, Trager C, Holmqvist BM, Abrahamsson J, Peuchmaur M, Michon J, Janoueix-Lerosey I, Kogner P, Delattre O, Martinsson T: Emergence of new ALK mutations at relapse of neuroblastoma. *J Clin Oncol* 32:2727-2734, 2014
  366. Scoazec JY, Couvelard A: Gastroenteropancreatic neuroendocrine tumors: what must the pathologist know and do in 2014? *Ann Pathol* 34:40-50, 2014
  367. Scoazec JY: A granulomatous colitis? *Ann Pathol* 34:238-241, 2014
  368. Scoazec JY: TENpath network, an expertise pathology network dedicated to sporadic and inherited adult neuroendocrine tumors: first evaluation and first lessons. *Ann Pathol* 34:34-39, 2014
  369. Sebti J, Desseigne F, Saltel P: Prodromal depression in pancreatic cancer: retrospective evaluation on ten patients. *Palliat Support Care* 13:801-807, 2015
  370. Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, Tredan O, Tournigand C, Colombo N, Dudnichenko AS, Westermann A, Friccius-Quecke H, Lordick F: Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. *Med Oncol* 31:76, 2014
  371. Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A, Lortholary A, Pujade-Lauraine E: A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. *Ann Oncol* 25:2191-2196, 2014
  372. Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, Delva R, Bay JO, Flechon A, Geoffrois L, Caty A, Soares DG, de RT, Fizazi K, Gligorov J, Miclea JM, Dubot C, Provent S, Temby I, Gaulet M, Horn E, Brindel I, Lotz JP: A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study. *Ann Oncol* 25:1775-1782, 2014
  373. Selmi A, de Saint-Jean M, Jallas AC, Garin E, Hogarty MD, Benard J, Puisieux A, Marabelle A, Valsesia-Wittmann S: TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. *Cancer Lett* 357:412-418, 2015
  374. Servagi-Vernat S, Giraud P, Fenoglietto P, Azria D, Lisbona A, de La RA, Zefkili S, Fau P, Resbeut M, Huger S, Peiffert D, Meyer P, Noel G, Mazurier J, Latorzeff I, Biston MC, Pommier P, Ledu D, Garcia R, Chauvet B, Dudouet P, Belhomme S, Kantor G, Mahe MA: [Impact of dynamic IMRT and tomotherapy in pelvic

- cancers: a prospective dosimetric study with 51 patients]. *Cancer Radiother* 18:111-118, 2014
375. Sicard A, Ducreux S, Rabeyrin M, Couzi L, McGregor B, Badet L, Scoazec JY, Bachelet T, Lepreux S, Visentin J, Merville P, Fremeaux-Bacchi V, Morelon E, Taupin JL, Dubois V, Thaunat O: Detection of C3d-Binding Donor-Specific Anti-HLA Antibodies at Diagnosis of Humoral Rejection Predicts Renal Graft Loss. *J Am Soc Nephrol* 2014
376. Simonnet H, Vigneron A, Pouyssegur J: Conventional techniques to monitor mitochondrial oxygen consumption. *Methods Enzymol* 542:151-161, 2014
377. Skibola CF, Berndt SI, Vijai J, Conde L, Wang Z, Yeager M, de Bakker PI, Birmann BM, Vajdic CM, Foo JN, Bracci PM, Vermeulen RC, Slager SL, de SS, Wang SS, Linet MS, Salles G, Lan Q, Severi G, Hjalgrim H, Lightfoot T, Melbye M, Gu J, Ghesquieres H, Link BK, Morton LM, Holly EA, Smith A, Tinker LF, Teras LR, Krickler A, Becker N, Purdue MP, Spinelli JJ, Zhang Y, Giles GG, Vineis P, Monnereau A, Bertrand KA, Albanes D, Zeleniuch-Jacquotte A, Gabbas A, Chung CC, Burdett L, Hutchinson A, Lawrence C, Montalvan R, Liang L, Huang J, Ma B, Liu J, Adami HO, Glimelius B, Ye Y, Nowakowski GS, Dogan A, Thompson CA, Habermann TM, Novak AJ, Liebow M, Witzig TE, Weiner GJ, Schenk M, Hartge P, De Roos AJ, Cozen W, Zhi D, Akers NK, Riby J, Smith MT, Lacher M, Villano DJ, Maria A, Roman E, Kane E, Jackson RD, North KE, Diver WR, Turner J, Armstrong BK, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, McKay J, Brooks-Wilson AR, Zheng T, Holford TR, Chamosa S, Kaaks R, Kelly RS, Ohlsson B, Travis RC, Weiderpass E, Clavel J, Giovannucci E, Kraft P, Virtamo J, Mazza P, Cocco P, Ennas MG, Chiu BC, Fraumeni JF, Jr., Nieters A, Offit K, Wu X, Cerhan JR, Smedby KE, Chanock SJ, Rothman N: Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. *Am J Hum Genet* 95:462-471, 2014
378. Smekens F, Letang JM, Noblet C, Chiavassa S, Delpon G, Freud N, Rit S, Sarrut D: Split exponential track length estimator for Monte-Carlo simulations of small-animal radiation therapy. *Phys Med Biol* 59:7703-7715, 2014
379. Soubeyran P, Bellera C, Goyard J, Heitz D, Cure H, Rousselot H, Albrand G, Servent V, Jean OS, van P, I, Kurtz JE, Perin S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Mathoulin-Pelissier S, Rainfray M: Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. *PLoS One* 9:e115060, 2014
380. Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Muller MC, Radich JP, Shah NP: Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. *Leuk Res* 38:10-20, 2014

381. Stoltz A, Gagniere J, Dupre A, Rivoire M: Radiofrequency ablation for colorectal liver metastases. *J Visc Surg* 151 Suppl 1:S33-S44, 2014
382. Surinach C, Balme B, Thomas L, Dalle S: Melanoma in regression. *Ann Dermatol Venereol* 141:147-149, 2014
383. Tallon L, Luangphakdy D, Ruffion A, Colombel M, Devonec M, Champetier D, Paparel P, Decaussin-Petrucci M, Perrin P, Vlaeminck-Guillem V: Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness. *Int J Mol Sci* 15:13299-13316, 2014
384. Talvas J, Garrait G, Goncalves-Mendes N, Rouanet J, Vergnaud-Gauduchon J, Kwiatkowski F, Bachmann P, Bouteloup C, Bienvenu J, Vasson MP: Immunonutrition stimulates immune functions and antioxidant defense capacities of leukocytes in radiochemotherapy-treated head & neck and esophageal cancer patients: A double-blind randomized clinical trial. *Clin Nutr* 34:810-817, 2015
385. Taupin T, Ltaief BA, Baggio E, Gensburger M, Pialat JB: [Comparison of 3T dacryo-MRI by instillation with dacryo-CT scan for evaluation of epiphora]. *J Fr Ophtalmol* 37:526-534, 2014
386. Telouk P, Puisieux A, Fujii T, Balter V, Bondanese VP, Morel AP, Clapisson G, Lamboux A, Albarede F: Copper isotope effect in serum of cancer patients. A pilot study. *Metallomics* 2014
387. Tessereau C, Lesecque Y, Monnet N, Buisson M, Barjhoux L, Leone M, Feng B, Goldgar DE, Sinilnikova OM, Mousset S, Duret L, Mazoyer S: Estimation of the RNU2 macrosatellite mutation rate by BRCA1 mutation tracing. *Nucleic Acids Res* 42:9121-9130, 2014
388. Testoni B, Levrero M, Durantel D: Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question? *Gut* 63:3-4, 2014
389. Thepot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing KA, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C: Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. *Am J Hematol* 89:410-416, 2014
390. Thomas X: Current indications of allogeneic stem cell transplant in adults with acute myeloid leukemia. *Bull Cancer* 101:856-865, 2014
391. Thomas XG, Arthur C, Delaunay J, Jones M, Berrak E, Kantarjian HM: A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. *Clin Lymphoma Myeloma Leuk* 14:68-72, 2014

392. Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, Chassagne-Clement C, Inwards DJ, Gargi T, Johnston PB, Nicolas-Virelizier E, Macon WR, Peix M, Micallef IN, Sebban C, Nowakowski GS, Porrata LF, Weiner GJ, Witzig TE, Habermann TM, Link BK: Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. *J Clin Oncol* 32:3506-3512, 2014
393. Toffart AC, Sakhri L, Girard N, Couraud S, Merle P, Fournel P, Perol M, Souquet PJ, Timsit JF, Moro-Sibilot D: [Assessment of a tool for decision making in case of worsening condition of cancer patients]. *Rev Mal Respir* 32:66-72, 2015
394. Toffart AC, Timsit JF, Couraud S, Merle P, Moro-Sibilot D, Perol M, Mastroianni B, Souquet PJ, Girard N, Jeannin G, Romand P, Chatellain P, Vesin A, Brambilla C, Brambilla E: Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). *Lung Cancer* 83:182-188, 2014
395. Toulmonde M, Bonvalot S, Meeus P, Stoeckle E, Riou O, Isambert N, Bompas E, Jafari M, Delcambre-Lair C, Saada E, Le CA, Le PC, Blay JY, Piperno-Neumann S, Chevreau C, Bay JO, Brouste V, Terrier P, Ranchere-Vince D, Neuville A, Italiano A: Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. *Ann Oncol* 25:735-742, 2014
396. Tredan O, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, Prausova J, Hardy-Bessard AC, Arance A, Mukhopadhyay P, Aloe A, Roche H: Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. *Clin Breast Cancer* 15:8-15, 2015
397. Tredan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barriere J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthelemy P: Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. *Target Oncol* 10:189-198, 2015
398. Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, Bourcier AV, Eymard JC, Spaeth D, Bachelot T: Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. *Ann Oncol* 26:120-125, 2015
399. Trepo C, Chan HL, Lok A: Hepatitis B virus infection. *Lancet* 384:2053-2063, 2014
400. Trepo C: A brief history of hepatitis milestones. *Liver Int* 34 Suppl 1:29-37, 2014
401. Tubbs E, Theurey P, Vial G, Bendridi N, Bravard A, Chauvin MA, Ji-Cao J, Zoulim F, Bartosch B, Ovize M, Vidal H, Rieusset J: Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin

- signaling and is implicated in hepatic insulin resistance. *Diabetes* 63:3279-3294, 2014
402. Tulchinsky E, Pringle JH, Caramel J, Ansieau S: Plasticity of melanoma and EMT-TF reprogramming. *Oncotarget* 5:1-2, 2014
  403. Urban S, Bartenschlager R, Kubitz R, Zoulim F: Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes. *Gastroenterology* 147:48-64, 2014
  404. Uzan B, Poglio S, Gerby B, Wu CL, Gross J, Armstrong F, Calvo J, Cahu X, Deswarte C, Dumont F, Passaro D, Besnard-Guerin C, Leblanc T, Baruchel A, Landman-Parker J, Ballerini P, Baud V, Ghysdael J, Baleyrier F, Porteu F, Pflumio F: Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression. *EMBO Mol Med* 6:821-834, 2014
  405. Vallin M, Guillaud O, Boillot O, Hervieu V, Scoazec JY, Dumortier J: Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis. *Liver Transpl* 20:1064-1071, 2014
  406. Vasson MP, Talvas J, Perche O, Dillies AF, Bachmann P, Pezet D, Achim AC, Pommier P, Racadot S, Weber A, Ramdani M, Kwiatkowski F, Bouteloup C: Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: a randomized clinical trial. *Clin Nutr* 33:204-210, 2014
  407. Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, Bernard D, Bonnefoi H, MacGrogan G, Iggo RD: Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells. *Breast Cancer Res* 16:504, 2014
  408. Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Cure H, Pujade-Lauraine E: Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. *J Clin Oncol* 32:320-326, 2014
  409. Vernez D, Milon A, Vuilleumier L, Bulliard JL, Koechlin A, Boniol M, Dore JF: A general model to predict individual exposure to solar UV by using ambient irradiance data. *J Expo Sci Environ Epidemiol* 25:113-118, 2015
  410. Vernin C, Thenoz M, Pinatel C, Gessain A, Gout O, Delfau-Larue MH, Nazaret N, Legras-Lachuer C, Wattel E, Mortreux F: HTLV-1 bZIP factor HBZ promotes cell proliferation and genetic instability by activating OncomiRs. *Cancer Res* 74:6082-6093, 2014

411. Vignot S, Bay JO, Andre T, Blay JY, Goncalves A, Massard C, Orbach D, Wislez M, Thariat J, Magne N: [Major advances in Oncology in 2013: the editorial board of the Bulletin du Cancer point of view]. *Bull Cancer* 101:75-92, 2014
412. Vindrieux D, Devailly G, Augert A, Le CB, Ferrand M, Pigny P, Payen L, Lambeau G, Perrais M, Aubert S, Simonnet H, Dante R, Bernard D: Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth. *Oncotarget* 5:1004-1013, 2014
413. Virlogeux V, Pradat P, Bailly F, Funingana G, Goncalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F: Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. *J Viral Hepat* 21:e98-e107, 2014
414. Vlaeminck-Guillem V, Gillet G, Rimokh R: SRC: marker or actor in prostate cancer aggressiveness. *Front Oncol* 4:222, 2014
415. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W: EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. *Lancet Oncol* 15:e395-e403, 2014
416. Wiel C, Lallet-Daher H, Gitenay D, Gras B, Le CB, Augert A, Ferrand M, Prevarskaya N, Simonnet H, Vindrieux D, Bernard D: Endoplasmic reticulum calcium release through ITPR2 channels leads to mitochondrial calcium accumulation and senescence. *Nat Commun* 5:3792, 2014
417. Willemze R, Suci S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrere F, Sr., Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeyer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de WT: High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. *J Clin Oncol* 32:219-228, 2014
418. Wislez M, Barlesi F, Besse B, Mazieres J, Merle P, Cadranet J, Audigier-Valette C, Moro-Sibilot D, Gautier-Felizot L, Goupil F, Renault A, Quoix E, Souquet PJ, Madroszyck A, Corre R, Perol D, Morin F, Zalcman G, Soria JC: Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. *J Clin Oncol* 32:1256-1261, 2014
419. Wozniak A, Rutkowski P, Schoffski P, Ray-Coquard I, Hostein I, Schildhaus HU, Le CA, Bylina E, Limon J, Blay JY, Siedlecki JA, Wardelmann E, Sciot R, Coindre JM, Debiec-Rychter M: Tumor genotype is an independent prognostic

- factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST. *Clin Cancer Res* 20:6105-6116, 2014
420. Xerri L, Bachy E, Fabiani B, Canioni D, Chassagne-Clement C, Dartigues-Cuilleres P, Charlotte F, Brousse N, Rousselet MC, Foussard C, Brice P, Feugier P, Morschhauser F, Sonet A, Olive D, Salles G: Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. *Hum Pathol* 45:2085-2093, 2014
421. Yu DM, Li XH, Mom V, Lu ZH, Liao XW, Han Y, Pichoud C, Gong QM, Zhang DH, Zhang Y, Deny P, Zoulim F, Zhang XX: N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. *J Hepatol* 60:515-522, 2014
422. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernandez-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T: BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. *Cancer Cell* 26:428-442, 2014
423. Zamora-Ros R, Touillaud M, Rothwell JA, Romieu I, Scalbert A: Measuring exposure to the polyphenol metabolome in observational epidemiologic studies: current tools and applications and their limits. *Am J Clin Nutr* 100:11-26, 2014
424. Zannetti C, Parroche P, Panaye M, Roblot G, Gruffat H, Manet E, Debaud AL, Plumas J, Vey N, Caux C, Bendriss-Vermare N, Hasan UA: TLR9 transcriptional regulation in response to double-stranded DNA viruses. *J Immunol* 193:3398-3408, 2014
425. Zhang N, Zhang P, Baier A, Cova L, Hosmane RS: Dual inhibition of HCV and HIV by ring-expanded nucleosides containing the 5:7-fused imidazo[4,5-e][1,3]diazepine ring system. In vitro results and implications. *Bioorg Med Chem Lett* 24:1154-1157, 2014